Brian T. Hill, Ph.D. - Publications

Affiliations: 
2000 Purdue University, West Lafayette, IN, United States 
Area:
Reactive organic intermediates

11/500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2001 Tichy SE, Hill BT, Campbell JL, Kenttämaa HI. Synthesis and characterization of a distonic nitrene ion: gas-phase reactivity of singlet and triplet N-phenyl-3-nitrenopyridinium ion. Journal of the American Chemical Society. 123: 7923-4. PMID 11493073 DOI: 10.1021/ja0157088  0.321
2000 Artau A, Nizzi KE, Hill BT, Sunderlin LS, Wenthold PG. Bond dissociation energy in trifluoride ion Journal of the American Chemical Society. 122: 10667-10670. DOI: 10.1021/Ja001613E  0.609
1999 Seburg RA, Hill BT, Squires RR. Synthesis, properties and reactivity of the phenylcarbene anion in the gas phase† Journal of the Chemical Society-Perkin Transactions 1. 2249-2256. DOI: 10.1039/A905870B  0.644
1999 Seburg RA, Hill BT, Jesinger RA, Squires RR. The phenylcarbyne anion [3] Journal of the American Chemical Society. 121: 6310-6311. DOI: 10.1021/Ja984026Q  0.572
1999 Hill BT, Poutsma JC, Chyall LJ, Hu J, Squires RR. Distonic ions of the 'Ate' class Journal of the American Society For Mass Spectrometry. 10: 896-906. DOI: 10.1016/S1044-0305(99)00053-7  0.723
1998 Hill BT, Squires RR. Synthesis and characterization of the negative ion of non-Kekulé benzene Journal of the Chemical Society-Perkin Transactions 1. 1027-1036. DOI: 10.1039/A707470K  0.664
1998 Wenthold PG, Hu J, Hill BT, Squires RR. Gas-phase negative ion chemistry of molecular fluorine. Synthesis of distonic radical anions and related species ☆ International Journal of Mass Spectrometry. 179: 173-183. DOI: 10.1016/S1387-3806(98)14077-0  0.725
1998 Wenthold PG, Hu J, Hill BT, Squires RR. Gas-phase negative ion chemistry of molecular fluorine. Synthesis of distonic radical anions and related species International Journal of Mass Spectrometry. 179: 173-183.  0.617
1998 Hill BT, Squires RR. Synthesis and characterization of the negative ion of non-Kekulé benzene Journal of the Chemical Society. Perkin Transactions 2. 1027-1035.  0.439
1997 Poutsma JC, Seburg RA, Chyall LJ, Sunderlin LS, Hill BT, Hu J, Squires RR. Combining electrospray ionization and the flowing afterglow method. Rapid Communications in Mass Spectrometry : Rcm. 11: 489-93. PMID 9131819 DOI: 10.1002/(Sici)1097-0231(199703)11:5<489::Aid-Rcm896>3.0.Co;2-L  0.704
1997 Hu J, Hill BT, Squires RR. New approach to carbene chemistry via distonic carbene ions. A case of spin-forbidden proton transfer and carbene-biradical tautomerism Journal of the American Chemical Society. 119: 11699-11700. DOI: 10.1021/Ja9727070  0.604
Low-probability matches (unlikely to be authored by this person)
2003 Edwards GD, Cantrell CA, Stephens S, Hill B, Goyea O, Shetter RE, Mauldin RL, Kosciuch E, Tanner DJ, Eisele FL. Chemical ionization mass spectrometer instrument for the measurement of tropospheric HO2 and RO2. Analytical Chemistry. 75: 5317-27. PMID 14710808  0.217
1999 Seburg RA, Hill BT, Squires RR. Synthesis, properties and reactivity of the phenylcarbene anion in the gas phase Journal of the Chemical Society. Perkin Transactions 2. 2249-2256.  0.194
2000 Kruczynski A, Etiévant C, Perrin D, Imbert T, Colpaert F, Hill BT. Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases. British Journal of Cancer. 83: 1516-24. PMID 11076662 DOI: 10.1054/bjoc.2000.1428  0.185
2000 van Hille B, Etiévant C, Barret JM, Kruczynski A, Hill BT. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action. Anti-Cancer Drugs. 11: 829-41. PMID 11142691 DOI: 10.1097/00001813-200011000-00007  0.183
2002 Barret JM, Kruczynski A, Etiévant C, Hill BT. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. Cancer Chemotherapy and Pharmacology. 49: 479-86. PMID 12107553 DOI: 10.1007/s00280-002-0451-5  0.181
2003 Etiévant C, Kruczynski A, Barret JM, Perrin D, Hill BT. Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II. Biochemical Pharmacology. 65: 755-63. PMID 12628489 DOI: 10.1016/S0006-2952(02)01564-2  0.171
2002 Barret JM, Etiévant C, Baudouin C, Skov K, Charvéron M, Hill BT. F 11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells. Anticancer Research. 22: 187-92. PMID 12017285  0.17
2000 Barret JM, Montaudon D, Etiévant C, Perrin D, Kruczynski A, Robert J, Hill BT. Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II. Anticancer Research. 20: 4557-62. PMID 11205304  0.169
2002 Barret JM, Cadou M, Hill BT. Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid. Biochemical Pharmacology. 63: 251-8. PMID 11841800 DOI: 10.1016/S0006-2952(01)00835-8  0.167
2003 Jensen LH, Renodon-Cornière A, Nitiss KC, Hill BT, Nitiss JL, Jensen PB, Sehested M. A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha. Biochemical Pharmacology. 66: 623-31. PMID 12906927 DOI: 10.1016/S0006-2952(03)00342-3  0.167
2001 Likhotvorik I, Zhu Z, Tae EL, Tippmann E, Hill BT, Platz MS. Carbomethoxychlorocarbene: spectroscopy, theory, chemistry and kinetics. Journal of the American Chemical Society. 123: 6061-8. PMID 11414839 DOI: 10.1021/Ja004235M  0.165
2000 Barret JM, Hill BT, Olive PL. Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases. British Journal of Cancer. 83: 1740-6. PMID 11104575 DOI: 10.1054/bjoc.2000.1514  0.164
2000 Etiévant C, Kruczynski A, Barret JM, Perrin D, van Hille B, Guminski Y, Hill BT. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemotherapy and Pharmacology. 46: 101-13. PMID 10972479 DOI: 10.1007/s002800000133  0.162
2000 Perrin D, van Hille B, Barret JM, Kruczynski A, Etiévant C, Imbert T, Hill BT. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action. Biochemical Pharmacology. 59: 807-19. PMID 10718339 DOI: 10.1016/S0006-2952(99)00382-2  0.16
2002 Hill BT, Zhu Z, Boeder A, Hadad CM, Platz MS. Bystander effects on carbene rearrangements: A computational study Journal of Physical Chemistry A. 106: 4970-4979. DOI: 10.1021/Jp020108W  0.143
2002 Kruczynski A, Ricome C, Waud WR, Hill BT. In vivo antitumor activity of F 11782, a non-intercalating dual catalytic inhibitor of topoisomerases I and II, against a panel of human tumor xenografts. Journal of Experimental Therapeutics & Oncology. 2: 219-27. PMID 12416026 DOI: 10.1046/j.1359-4117.2002.01037.x  0.138
2000 Lobert S, Fahy J, Hill BT, Duflos A, Etievant C, Correia JJ. Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line. Biochemistry. 39: 12053-62. PMID 11009620 DOI: 10.1021/Bi001038R  0.132
2004 Kruczynski A, Barret JM, Van Hille B, Chansard N, Astruc J, Menon Y, Duchier C, Créancier L, Hill BT. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3156-68. PMID 15131057 DOI: 10.1158/1078-0432.CCR-1305-2  0.129
2003 Romashin YN, Liu MTH, Hill BT, Platz MS. Sulfur ylides generated from the reaction of adamantylidene and phenylcarbene with sulfur substrates Tetrahedron Letters. 44: 6519-6521. DOI: 10.1016/S0040-4039(03)01589-2  0.125
2003 Sargent JM, Elgie AW, Williamson CJ, Hill BT. Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anti-Cancer Drugs. 14: 467-73. PMID 12853890 DOI: 10.1097/01.cad.0000078731.65608.aa  0.123
2022 Arustamyan M, Kibrik P, Hatipoglu D, Bungo B, Mentias A, Hill BT, Moudgil R. The Safety of Bruton's Tyrosine Kinase Inhibitors in B-cell Malignancies: A Systematic Review. European Journal of Haematology. PMID 36030394 DOI: 10.1111/ejh.13854  0.12
2022 Goldsmith SR, Ghobadi A, Dipersio JF, Hill B, Shadman M, Jain T. Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective. Transplantation and Cellular Therapy. PMID 35878743 DOI: 10.1016/j.jtct.2022.07.015  0.12
1990 Berger MR, Hellmann K, Hill BT, Schmähl D, Jens Zeller W. Foreword Cancer Treatment Reviews. 17: 107.  0.12
1988 Fichtinger-Schepman AM, Dijt FJ, Bedford P, van Oosterom AT, Hill BT, Berends F. Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques Iarc Scientific Publications. 321-328. PMID 3198216  0.108
2001 Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Critical Reviews in Oncology/Hematology. 40: 159-73. PMID 11682323 DOI: 10.1016/S1040-8428(01)00183-4  0.103
2003 Buchmueller KL, Hill BT, Platz MS, Weeks KM. RNA-tethered phenyl azide photocrosslinking via a short-lived indiscriminant electrophile. Journal of the American Chemical Society. 125: 10850-61. PMID 12952464 DOI: 10.1021/Ja035743+  0.102
2006 Hill BT. Ship collision with iceberg database 7th International Conference and Exhibition On Performance of Ships and Structures in Ice, Icetech 2006. 172-178.  0.102
2021 Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, ... ... Hill BT, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. PMID 34570876 DOI: 10.1182/blood.2021012888  0.099
2003 Hill BT, Platz MS. Matrix isolation photolysis study of tetrazolo[1,5-b]pyridazine Physical Chemistry Chemical Physics. 5: 1051-1058. DOI: 10.1039/B210123H  0.099
2017 Ali MM, Abounader DM, Rybicki LA, Yurch MA, Starn J, Ferraro C, Winslow V, Hamilton BK, Gerds AT, Liu H, Dean R, Hill BT, Pohlman B, Andresen S, Hanna R, et al. Comparative Effectiveness of Busulfan and Fludarabine Versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for AML/MDS. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28108271 DOI: 10.1016/j.bbmt.2017.01.077  0.098
2017 Andreadis C, Fenske TS, Hill BT, Stiff PJ, Grinblatt DL, Hsi ED, Kelley T, Richards KL, Kostakoglu L, Schöder H, Jung S, Pitcher B, Pike K, Plona T, Baugher R, et al. Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology. 35: TPS7566-TPS7566. DOI: 10.1200/jco.2017.35.15_suppl.tps7566  0.097
2016 Winter AM, Landsburg DJ, Hernandez-Ilizaliturri FJ, Reddy N, Smith S, Shadman M, Caimi P, Jagadeesh D, Smith MR, Hill BT. A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib Blood. 128: 1115-1115. DOI: 10.1182/blood.v128.22.1115.1115  0.096
2021 Hill B, Jagadeesh D, Pohlman B, Dean R, Parameswaran N, Chen J, Radivoyevitch T, Morrison A, Fada S, Dever M, Robinson S, Lindner D, Smith M, Saunthararajah Y. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. Seminars in Hematology. 58: 35-44. PMID 33509441 DOI: 10.1053/j.seminhematol.2020.11.008  0.095
2014 Wieduwilt MJ, Cerny J, Akard L, Ustun C, Ravandi F, Rossetti JM, Hill BT, Brown J(, Kellerman L, Van Syoc R, Reed W, Andreadis C. Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML) Blood. 124: 2268-2268. DOI: 10.1182/blood.V124.21.2268.2268  0.094
2014 Bumma N, Rybicki L, Caimi P, Jagadeesh D, Dean RM, Pohlman B, Smith MR, Hill BT. Comparison of Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma (BCL-U) Patient Outcomes: Intensive Therapy May Not Benefit BCL-U Blood. 124: 3065-3065. DOI: 10.1182/blood.v124.21.3065.3065  0.092
1998 Lobert S, Ingram JW, Hill BT, Correia JJ. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Molecular Pharmacology. 53: 908-15. PMID 9584218  0.091
2015 Winter AM, Rybicki LA, Shah S, Jagadeesh D, Gerds AT, Hamilton BK, Liu H, Dean RM, Sobecks R, Pohlman B, Andresen S, Smith MR, Kalaycio M, Bolwell BJ, Majhail NS, ... Hill BT, et al. Prognostic Value of Pre-Transplant PET Scan in Patients with Diffuse Large B-Cell (DLBCL) Lymphoma Undergoing Autologous Stem Cell Transplantation (ASCT) Blood. 126: 5495-5495. DOI: 10.1182/blood.V126.23.5495.5495  0.091
2012 Lukenbill J, Rybicki L, Sekeres MA, DiGiorgio M, Fraser T, Copelan A, Duong HK, Hill BT, Kalaycio M, Sobecks R, Hanna R, Bolwell BJ, Copelan EA. Defining Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood. 120: 3042-3042. DOI: 10.1182/blood.V120.21.3042.3042  0.089
1993 Price LA, Shaw HJ, Hill BT. Larynx preservation after initial non-cisplatin containing combination chemotherapy plus radiotherapy, as opposed to surgical intervention with or without radiotherapy in previously untreated advanced head and neck cancer: Final analysis after 12 years follow-up Journal of Laryngology and Otology. 107: 211-216. PMID 8509698  0.089
2018 Allen J, Ruano Mendez AL, Rybicki L, Sawalha Y, Jagadeesh D, Dean R, Pohlman B, Smith MR, Hsi ED, Hill BT. Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant. Therapeutic Advances in Hematology. 9: 81-87. PMID 29623179 DOI: 10.1177/2040620718759249  0.088
2019 Churnetski MC, Switchenko JM, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, ... ... Hill BT, et al. Prognostic Variables of Progression Free Survival in Mantle Cell Lymphoma after Autologous Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 25: S23-S24. DOI: 10.1016/J.Bbmt.2018.12.093  0.088
2000 Barret JM, Etiévant C, Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemotherapy and Pharmacology. 45: 471-6. PMID 10854134 DOI: 10.1007/s002800051021  0.088
2015 Hong S, Rybicki LA, Abounader DM, Bolwell BJ, Dean RM, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HK, Pohlman B, Sobecks R, Majhail NS. Association of Socioeconomic Status (SES) with Outcomes of Autologous Hematopoietic Cell Transplantation (ASCT) for Lymphoma Blood. 126: 4494-4494. DOI: 10.1182/blood.v126.23.4494.4494  0.087
2010 Hill BT, Copelan EA. Acute myeloid leukemia: when to transplant in first complete remission. Current Hematologic Malignancy Reports. 5: 101-8. PMID 20425403 DOI: 10.1007/s11899-010-0042-1  0.087
2016 Nazha A, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill BT, Kalaycio M, Liu H, Pohlman B, Sobecks R, Sekeres MA, Majhail NS. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies. Bone Marrow Transplantation. PMID 27721371 DOI: 10.1038/bmt.2016.254  0.087
2017 Hill BT, Ahn KW, Hu ZH, Aljurf M, Beitinjaneh A, Cahn JY, Cerny J, Kharfan-Dabaja MA, Ganguly S, Ghosh N, Grunwald MR, Inamoto Y, Kindwall-Keller T, Nishihori T, Olsson RF, et al. Assessment of Impact of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL). Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29032274 DOI: 10.1016/j.bbmt.2017.10.015  0.086
1990 Hill BT, Price LA. The role of adjuvant chemotherapy in the treatment of advanced head and neck cancer Acta Oncologica. 29: 695-703. PMID 2223138 DOI: 10.3109/02841869009092986  0.086
2012 Dean RM, Kalaycio M, Pohlman B, Sobecks R, Copelan EA, Hill BT, Rybicki L, Tench S, Bolwell BJ. Tandem Autologous Hematopoietic Progenitor Cell Transplantation (AHPCT) for High-Risk Hodgkin Lymphoma: Mature Results of a Prospective Trial Blood. 120: 1990-1990. DOI: 10.1182/blood.v120.21.1990.1990  0.086
2016 Mato AR, Lamanna N, Ujjani CS, Brander DM, Hill BT, Howlett C, Skarbnik AP, Cheson B, Zent CS, Pu JJ, Kiselev P, Bachow SH, Winter AM, Cruz A, Claxton DF, et al. Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients Blood. 128: 3222-3222. DOI: 10.1182/blood.v128.22.3222.3222  0.086
2019 Mian A, Wei W, Winter AM, Khouri J, Jagadeesh D, Anwer F, Gerds AT, Dean RM, Sobecks R, Pohlman B, Kalaycio M, Hamilton BK, Majhail NS, Hill BT. Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis Blood. 134: 4452-4452. DOI: 10.1182/blood-2019-127087  0.085
2015 Allen JM, Rybicki LA, Caimi PF, Jagadeesh D, Dean RM, Pohlman B, Smith MR, Kalaycio M, Hill BT. Standard Duration of Varicella Zoster Virus Prophylaxis May be Inadequate to Prevent Viral Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Front-Line Bendamustine Plus Rituximab Blood. 126: 4167-4167. DOI: 10.1182/blood.V126.23.4167.4167  0.085
2012 Hamilton BK, Rybicki L, Sekeres MA, Bolwell BJ, Kalaycio M, Hanna R, Dean RM, Sobecks R, Duong HK, Hill BT, Copelan EA. Racial Differences in Prognostic Factors and Outcomes in Patients Undergoing Allogeneic Hematopoietic Cell Transplant Blood. 120: 2020-2020. DOI: 10.1182/blood.v120.21.2020.2020  0.085
2012 Lukenbill J, Rybicki L, Sekeres MA, Copelan A, Zaman O, Haddad H, Duong HK, Hill BT, Kalaycio M, Sobecks R, Hanna R, Fraser T, DiGiorgio M, Bolwell BJ, Copelan EA. Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Incidence, Risk Factors, and Impact On Survival Blood. 120: 4481-4481. DOI: 10.1182/blood.V120.21.4481.4481  0.085
2014 Pophali PA, Rybicki LA, Fenner KB, Jagadeesh D, Dean RM, Pohlman B, Smith MR, Hill BT. Bulky Disease Does Not Adversely Affect Overall Survival in Early Stage Hodgkin Lymphoma: Role of Interim PET and Possible Omission of Radiotherapy in Select Patients Blood. 124: 4428-4428. DOI: 10.1182/blood.V124.21.4428.4428  0.085
2017 Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B, Kalaycio M, Sekeres MA, Smith MR, Hill BT. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. Clinical Lymphoma, Myeloma & Leukemia. PMID 28778620 DOI: 10.1016/j.clml.2017.07.003  0.084
2016 Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, ... ... Hill BT, et al. Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes. British Journal of Haematology. PMID 26953041 DOI: 10.1111/Bjh.13975  0.084
2019 Awan FT, Thirman MJ, Patel-Donnelly D, Assouline S, Rao AV, Ye W, Hill B, Sharman JP. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. Leukemia & Lymphoma. 1-6. PMID 30633573 DOI: 10.1080/10428194.2018.1562180  0.084
2019 Mukhija D, Savani M, Shaikh S, Shah S, Rybicki L, Winter A, Jagadeesh D, Gerds AT, Dean RM, Wilke C, Sobecks RM, Pohlman B, Bolwell B, Kalaycio ME, Hamilton BK, ... ... Hill BT, et al. Post-Transplant Radiation Had No Impact on Survival in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma Biology of Blood and Marrow Transplantation. 25: S407. DOI: 10.1016/J.Bbmt.2018.12.825  0.083
2015 Mustafa Ali M, Abounader DM, Rybicki LA, Yurch MA, Starn J, Ferraro C, Winslow V, Hamilton BK, Gerds AT, Liu H, Dean R, Hill BT, Pohlman B, Andresen S, Hanna R, et al. Comparative Effectiveness of Fludarabine and Busulfan Versus Fludarabine and 400 cGy Total Body Irradiation Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation for AML/MDS Blood. 126: 1920-1920. DOI: 10.1182/blood.V126.23.1920.1920  0.083
2014 Sobecks RM, Thomas D, Zhang A, Saleh MM, Rybicki L, Yurch MA, Duong HK, Gerds A, Hamilton BK, Dean RM, Hill BT, Hanna R, Bolwell BJ, Kalaycio ME, Majhail NS, et al. Association of Donor Killer Immunoglobulin-like Receptor (KIR) Genotype with Outcome after HLA-Matched Related Donor Hematopoietic Cell Transplantation for AML Blood. 124: 2566-2566. DOI: 10.1182/blood.V124.21.2566.2566  0.083
2001 Hill BT. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Current Pharmaceutical Design. 7: 1199-212. PMID 11472262 DOI: 10.2174/1381612013397456  0.083
2018 Wang M, Locke FL, Munoz J, Goy A, Holmes HE, Siddiqi T, Flinn I, McSweeney PA, Reagan PM, Hill BT, Jacobson CA, Rizzieri DA, Heffner LT, Jaglowski SM, Miklos DB, et al. ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma. Journal of Clinical Oncology. 36: TPS3102-TPS3102. DOI: 10.1200/JCO.2018.36.15_suppl.TPS3102  0.082
2011 Hill BT, Collie AM, Radivoyevitch T, Hsi ED, Sweetenham J. Cell of Origin Determination in Diffuse Large B-Cell Lymphoma: Performance of Immunohistochemical (IHC) Algorithms and Ability to Predict Outcome Blood. 118: 950-950. DOI: 10.1182/blood.v118.21.950.950  0.082
2018 Hill BT, Dean RM, Jagadeesh D, Mejia Garcia AV, Pohlman B, Winter AM, Krauspe E, Collier P, D'Andrea C, Morrison A, Lehmann S, Tomlinson BK, Cooper B, de Lima M, Ondrejka SL, et al. Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Blood. 132: 1692-1692. DOI: 10.1182/BLOOD-2018-99-113381  0.082
2015 Vandermeer J, Winter AM, Gopal AK, Cassaday RD, Hill BT, Shustov AR, Cowan AJ, Maloney DG, Shadman M, Till BG, Soma L, Press OW, Smith SD. Poor Outcomes Among Patients Failing Dose-Adjusted EPOCH in Aggressive Lymphoma: A Collaborative, Retrospective Study Blood. 126: 1518-1518. DOI: 10.1182/blood.v126.23.1518.1518  0.082
2011 Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G, Rybicki LA, Kalaycio M, Maciejewski JP, Houghton JA, Almasan A. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood. 118: 3579-90. PMID 21772052 DOI: 10.1182/Blood-2011-03-340364  0.082
2014 Jagadeesh D, Rybicki L, Abounader DM, Hill BT, Dean RM, Duong HK, Sobecks RM, Hamilton BK, Gerds A, Ferraro C, Green G, Cherni K, Pohlman B, Kalaycio ME, Bolwell BJ, et al. Long Term Outcomes after Autologous Stem Cell Transplantation for Peripheral T Cell Lymphomas Blood. 124: 1200-1200. DOI: 10.1182/blood.V124.21.1200.1200  0.082
2012 Hill BT, Sweetenham J. Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. Leukemia & Lymphoma. 53: 763-9. PMID 21992676 DOI: 10.3109/10428194.2011.626882  0.081
2012 Kalaycio M, Bolwell BJ, Rybicki L, Copelan E, Duong HK, Hill BT, Dean RM, Pohlman B, Andresen S, Tench S, Sobecks R. Dual Cord Blood Unit (dCBU) Transplantation Increases Short-Term Morbidity, but Has Similar Long-Term Outcome Compared to Matched Unrelated Donor (MUD) Transplantation After Myeloablative Conditioning. Blood. 120: 3137-3137. DOI: 10.1182/blood.v120.21.3137.3137  0.08
2017 Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, et al. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 1414-1427. PMID 29118233 DOI: 10.6004/Jnccn.2017.0165  0.08
2016 Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. PMID 27601462 DOI: 10.1182/blood-2016-05-716977  0.08
2017 Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, et al. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017722157. PMID 28475457 DOI: 10.1200/JCO.2017.72.2157  0.08
2017 Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, ... Hill BT, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England Journal of Medicine. PMID 29226797 DOI: 10.1056/Nejmoa1707447  0.079
2012 Tavadze M, Mossad S, Rybicki L, Avery R, Yurch M, Pohlman B, Duong HK, Dean RM, Hill BT, Andresen S, Hanna R, Copelan EA, Bolwell BJ, Kalaycio M, Sobecks R. Risk Factors for Vancomycin Resistant Enterococcus (VRE) Infection and Its Influence On Survival After Allogeneic Hematopoietic Progenitor Cell Transplantation (aHPCT) Blood. 120: 4147-4147. DOI: 10.1182/blood.V120.21.4147.4147  0.079
2012 Hamilton BK, Rybicki L, Tench S, Haddad H, Bolwell BJ, Hanna R, Sobecks R, Dean RM, Duong HK, Hill BT, Copelan EA, Kalaycio M. Mycophenolate Mofetil Is a Suitable Substitute for Methotrexate for Graft Versus Host Disease Prevention in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Sibling Donors Blood. 120: 1952-1952. DOI: 10.1182/blood.v120.21.1952.1952  0.079
2019 Singer S, Sharma N, Dean R, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, ... ... Hill B, et al. BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. Bone Marrow Transplantation. PMID 30718797 DOI: 10.1038/s41409-019-0463-y  0.079
2018 Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaack K, et al. Toxicities and outcomes of 621 ibrutinib-treated chronic lymphocytic leukemia patients in the United States: a real-world analysis. Haematologica. PMID 29419429 DOI: 10.3324/haematol.2017.182907  0.079
2012 Hamilton BK, Bolwell BJ, Kalaycio M, Rybicki L, Hanna R, Sobecks R, Pohlman B, Andresen S, Dean RM, Duong HK, Hill BT, Copelan EA. Long-Term Follow-up of a Randomized Trial Comparing Cyclosporine and Short Course Methotrexate with Cyclosporine and Mycophenolate Mofetil for Graft Versus Host Disease Prophylaxis in Myeloablative HLA-Identical Sibling Hematopoietic Cell Transplantation. Blood. 120: 3073-3073. DOI: 10.1182/blood.v120.21.3073.3073  0.079
2018 Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, et al. Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. PMID 29880613 DOI: 10.3324/haematol.2018.193615  0.079
1999 Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F, Kruczynski A. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. European Journal of Cancer (Oxford, England : 1990). 35: 512-20. PMID 10448309 DOI: 10.1016/S0959-8049(98)00416-X  0.079
2020 Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, ... Hill BT, et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902104. PMID 32401634 DOI: 10.1200/JCO.19.02104  0.078
2015 Mato A, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Rago A, Zent CS, Feldman T, et al. Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study Blood. 126: 719-719. DOI: 10.1182/blood.V126.23.719.719  0.078
2016 William BM, Wang T, Haagenson MD, de Lima MJ, Fernandez-Vina MA, Stephen S, Lee SJ, Hill BT. Impact of Human Leukocyte Antigen (HLA) Alleles on Outcomes of Allogeneic Transplantation (Allo-HCT) for B-Cell Non-Hodgkin Lymphomas (B-NHL); A CIBMTR Analysis Blood. 128: 3491-3491. DOI: 10.1182/Blood.V128.22.3491.3491  0.078
2009 Hill BT, Rybicki L, Bolwell BJ, Smith S, Dean R, Kalaycio ME, Pohlman B, Tench S, Sobecks R, Andresen S, Copelan E, Sweetenham JW. Non-Relapse Mortality Exceeds Relapse Mortality Six Years After Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma. Blood. 114: 3325-3325. DOI: 10.1182/blood.v114.22.3325.3325  0.077
2022 Zijlstra JM, Follows G, Casasnovas RO, Vermaat JSP, Kalakonda N, Choquet S, Hill B, Thieblemont C, Cavallo F, Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi P, Gurion R, et al. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. Cancers. 14. PMID 35159058 DOI: 10.3390/cancers14030791  0.077
2013 Hanna R, Bolwell BJ, Sobecks R, Pohlman B, Jagadeesh D, Duong HK, Hill BT, Cherni K, Ferraro C, Green G, Hamilton BK, Rybicki L, Kalaycio M. Long-Term Outcome Of Adolescents and Young Adults (AYA) After Autologous Transplantation For Lymphoma; Single Center Experience With Bu-CY-VP16 Conditioning Therapy Blood. 122: 4644-4644. DOI: 10.1182/blood.V122.21.4644.4644  0.077
2015 Papadantonakis N, Rouphail B, Xuefei J, Dean RM, Hill BT, Pohlman B, Smith MR, Jagadeesh D. The Role of Post- Treatment Imaging in Detection of Relapsed Disease in Classical Hodgkin Lymphoma: The Cleveland Clinic Experience Blood. 126: 5006-5006. DOI: 10.1182/blood.V126.23.5006.5006  0.077
2014 Jagadeesh D, Rybicki L, Abounader DM, Hill BT, Dean RM, Duong HK, Sobecks RM, Hamilton BK, Gerds A, Ferraro C, Green G, Cherni K, Pohlman B, Kalaycio ME, Bolwell BJ, et al. Autologous Stem Cell Transplantation for Follicular Lymphoma in the Era of Rutiximab: Cleveland Clinic Experience Blood. 124: 1201-1201. DOI: 10.1182/blood.V124.21.1201.1201  0.077
2019 Kittai AS, Gordon MJ, Mian A, Fitzgerald L, Bishop J, Stephens DM, Nagle SJ, Hill BT, Danilov A. Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis Blood. 134: 780-780. DOI: 10.1182/blood-2019-124694  0.076
2013 Visconte V, Mahfouz RZ, Tabarroki A, Hasrouni E, Rogers HJ, Saunthararajah Y, Hill BT, Kalaycio M, Sekeres MA, Barnard J, Tiu RV. BCL-2 Family Of Genes Is a Key Regulator In The Pathogenesis Of SF3B1 Mutant and Wild Type MDS With Ring Sideroblasts and Represents a Novel Drug Target In This Disease Blood. 122: 263-263. DOI: 10.1182/blood.v122.21.263.263  0.076
2021 Mian A, Hill BT. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. Expert Opinion On Biological Therapy. PMID 33566715 DOI: 10.1080/14712598.2021.1889510  0.076
2014 Sharma A, Janocha AJ, Hill BT, Smith MR, Erzurum SC, Almasan A. Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells. Molecular Cancer Research : McR. 12: 1205-15. PMID 25061101 DOI: 10.1158/1541-7786.Mcr-14-0124  0.076
2013 Fenner KB, Rybicki L, Jagadeesh D, Dean RM, Pohlman B, Smith MR, Hill BT. Transformed Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated With Salvage Rituximab, Ifosfamide, Carboplatin and Etoposide (R-ICE) Have Superior Overall Survival Than Patients With De Novo DLBCL Blood. 122: 3038-3038. DOI: 10.1182/blood.V122.21.3038.3038  0.076
2013 Caimi PF, Sobecks R, Fu P, Cooper BW, Campagnaro EL, William BM, Abu-Arja R, Kolk MJ, Creger RJ, Duong HK, Hill BT, Bolwell BJ, Kalaycio M, de Lima M, Lazarus HM. Second Umbilical Cord Blood Transplant (UCBT2) In Adult Patients With Engraftment Failure Or Autologous Hematopoiesis After UCBT Blood. 122: 2117-2117. DOI: 10.1182/blood.v122.21.2117.2117  0.076
2021 Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, et al. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. British Journal of Haematology. PMID 34581433 DOI: 10.1111/bjh.17865  0.076
2016 Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, et al. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology. PMID 27977057 DOI: 10.1111/bjh.14464  0.075
2020 Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. The Lancet. Haematology. 7: e511-e522. PMID 32589977 DOI: 10.1016/S2352-3026(20)30120-4  0.075
2019 Mian A, Aboseif A, Wei W, Chakraborty R, Khouri J, Rudoni J, Winter AM, Patel S, Jagadeesh D, Dean RM, Pohlman B, Berg S, Cook JR, Hill BT, Mejia Garcia AV. Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status Blood. 134: 5248-5248. DOI: 10.1182/blood-2019-130396  0.075
2012 Duong HK, Koo A, Rybicki L, Copelan E, Kalaycio M, Sobecks R, Dean RM, Hill BT, Ondrejka SL, Abounader DM, Pohlman B, Bolwell BJ. Obese Patients Have Improved Survival Following Autologous Hematopoietic Stem Cell Transplantation Blood. 120: 1989-1989. DOI: 10.1182/blood.v120.21.1989.1989  0.075
2019 Hill B, Switchenko J, Martin P, Churnetski M, Sawalha Y, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson J, Barta S, Maldonado E, Gordon M, Danilov A, et al. MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR) Hematological Oncology. 37: 405-407. DOI: 10.1002/Hon.75_2631  0.075
2016 Nazha A, Rybicki L, Abounader D, Bolwell B, Dean RM, Ferraro C, Gerds A, Jagadeesh D, Hamilton BK, Hill BT, Kalaycio ME, Liu H, Pohlman B, Sobecks RM, Starn J, et al. Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) after Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Older Patients with Myeloid Malignancies Biology of Blood and Marrow Transplantation. 22: S205-S206. DOI: 10.1016/j.bbmt.2015.11.599  0.075
2018 Sawalha Y, McMichael J, Rybicki L, Sussman TA, Mejia Garcia AV, Dean RM, Pohlman B, Hill BT, Jagadeesh D. Risk of Post-Transplant Lymphoproliferative Disorders (PTLD) in Solid Organ Transplantation Patients with EBV Viremia Blood. 132: 4202-4202. DOI: 10.1182/blood-2018-99-114686  0.074
2022 Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, ... ... Hill B, et al. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. Journal of the National Comprehensive Cancer Network : Jnccn. 20: 622-634. PMID 35714675 DOI: 10.6004/jnccn.2022.0031  0.074
2016 Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, ... ... Hill BT, et al. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. British Journal of Haematology. PMID 27443247 DOI: 10.1111/Bjh.14228  0.074
2020 Mian A, Wei W, Winter AM, Khouri J, Jagadeesh D, Anwer F, Gerds AT, Dean RM, Sobecks R, Pohlman B, Hamilton BK, Majhail NS, Hill BT. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. Leukemia & Lymphoma. 1-9. PMID 33375873 DOI: 10.1080/10428194.2020.1864349  0.074
2017 Hill BT, Smith MR, Shelley M, Jagadeesh D, Dean RM, Pohlman B, Sweetenham JW, Bolwell BJ, Smith SD. A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma. Leukemia & Lymphoma. 1-5. PMID 28696812 DOI: 10.1080/10428194.2017.1347932  0.074
2016 Hong S, Rybicki L, Abounader DM, Bolwell BJ, Dean R, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS. Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma. Bone Marrow Transplantation. PMID 27111046 DOI: 10.1038/bmt.2016.107  0.074
2011 Hill BT, Rybicki L, Bolwell BJ, Smith S, Dean R, Kalaycio M, Pohlman B, Tench S, Sobecks R, Andresen S, Copelan E, Sweetenham J. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. British Journal of Haematology. 152: 561-9. PMID 21223255 DOI: 10.1111/j.1365-2141.2010.08549.x  0.074
2011 Hill BT, Rybicki L, Smith S, Dean R, Kalaycio M, Pohlman B, Sweetenham J, Tench S, Sobecks R, Andresen S, Copelan E, Bolwell BJ. Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. Leukemia & Lymphoma. 52: 986-93. PMID 21314484 DOI: 10.3109/10428194.2010.551154  0.074
2020 Wang M, Rossi JM, Munoz J, Goy A, Locke FL, Reagan PM, Jacobson CA, Hill BT, Holmes H, Jaglowski SM, Peng W, Zheng L, Fang X, Xue A, Rao AV, et al. Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial. Journal of Clinical Oncology. 38: 3023-3023. DOI: 10.1200/jco.2020.38.15_suppl.3023  0.074
2020 Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, et al. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Medicine. PMID 32969597 DOI: 10.1002/cam4.3470  0.074
1987 Hill BT, Whelan RDH, Gibby EM. In vitro phase II studies with anthracycline analogues and certain structurally-related anthraquinone compounds Clinical Trials Journal. 24: 13-22.  0.073
2019 Winter AM, Boughan KM, Khouri J, Caimi P, Anwer F, Cooper B, Jagadeesh D, Dean RM, Gerds AT, Sobecks R, Pohlman B, Kalaycio M, Hamilton BK, de Lima M, Majhail NS, ... Hill BT, et al. A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma Blood. 134: 5705-5705. DOI: 10.1182/blood-2019-124602  0.073
2019 Barr PM, Hill BT, Ma S, Baran AM, Bui A, Meacham PJ, Morrison A, Liesveld JL, Mulford DA, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Zent CS. A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Blood. 134: 360-360. DOI: 10.1182/BLOOD-2019-123404  0.073
2012 Dahiya S, Xie H, Hill BT, Peereboom D, Stevens GH, Murphy E, Chao S, Suh J, Ahluwalia MS. Primary Central Nervous System Lymphoma in Elderly Patients: Clinical Outcomes and Prognosis Blood. 120: 5083-5083. DOI: 10.1182/Blood.V120.21.5083.5083  0.073
2014 Hanna R, Rybicki L, Abounader D, Bolwell BJ, Dean RM, Duong HK, Flagg A, Gerds AT, Hamilton BK, Hill BT, Kalaycio ME, Sobecks R, Majhail NS. 10-Year Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT) in Adolescent and Young Adults (AYA) Blood. 124: 1183-1183. DOI: 10.1182/blood.v124.21.1183.1183  0.073
2019 Hong S, Rybicki L, Corrigan D, Hamilton BK, Sobecks R, Kalaycio M, Dean RM, Hill BT, Pohlman B, Jagadeesh D, Anwer F, Majhail NS. Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era Blood. 134: 4567-4567. DOI: 10.1182/blood-2019-124533  0.073
2015 Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D, Hanna R, Sobecks R, Duong H, Hill BT, Copelan E, Bolwell B, Kalaycio M. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. American Journal of Hematology. 90: 144-8. PMID 25353395 DOI: 10.1002/ajh.23882  0.072
2018 Caimi P, Jagadeesh D, Boughan KM, Dean RM, Cooper B, Pohlman B, Gallogly MM, Ondrejka SL, Moore E, Oduro KA, Hsi ED, de Lima M, Hill BT. Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study Blood. 132: 397-397. DOI: 10.1182/BLOOD-2018-99-115587  0.072
1987 Hill BT, Price LA, Macrae KD. The promising role of safe initial non-cisplatin-containing combination chemotherapy in nasopharyngeal tumors Cancer Investigation. 5: 517-522. PMID 3442729 DOI: 10.3109/07357908709020310  0.072
2013 Lukenbill J, Rybicki L, Sekeres MA, Zaman MO, Copelan A, Haddad H, Fraser T, DiGiorgio MJ, Hanna R, Duong H, Hill B, Kalaycio M, Sobecks R, Bolwell B, Copelan E. Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 720-4. PMID 23380342 DOI: 10.1016/j.bbmt.2013.01.022  0.072
2016 Hill BT, Woo Ahn K, Hu Z, Kalaycio M, Maziarz RT, Cortes JE, Alyea E, Popat UR, Sobecks RM, Saber W. Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL) Blood. 128: 2256-2256. DOI: 10.1182/blood.v128.22.2256.2256  0.072
2019 Cavallo F, Follows GA, Goy A, Vermaat J, Casasnovas R, Lavee O, Maerevoet M, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill BT, Jaeger U, Sancho J, et al. Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study Blood. 134: 5333-5333. DOI: 10.1182/Blood-2019-122900  0.071
2022 Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, Switchenko JM, Kahl B, Maddocks K, Grover NS, Qi K, Parisi L, Daly K, Zhu A, Salles G. Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102698. PMID 35763708 DOI: 10.1200/JCO.21.02698  0.071
2012 Bodo J, Hill BT, Zhao X, Portell CA, Lannutti BJ, Hsi ED. The PI3K Inhibitor GS-1101 (CAL-101) Synergistically Potentiates HDAC-Induced Proliferation Inhibition and Apoptosis Through the Activation of JNK in Lymphoma Cells Blood. 120: 3714-3714. DOI: 10.1182/blood.v120.21.3714.3714  0.071
2018 Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. The Lancet. Oncology. PMID 30518502 DOI: 10.1016/S1470-2045(18)30864-7  0.071
1998 Kruczynski A, Barret JM, Etiévant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochemical Pharmacology. 55: 635-48. PMID 9515574 DOI: 10.1016/S0006-2952(97)00505-4  0.071
2021 Orellana-Noia VM, Isaac K, Malecek MK, Bartlett NL, Voorhees TJ, Grover NS, Hwang SR, Bennani NN, Hu R, Hill BT, Mou E, Advani R, Carter J, David KA, Ballard HJ, et al. Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. Blood Advances. PMID 34448831 DOI: 10.1182/bloodadvances.2021004645  0.071
2017 Saygin C, Jia X, Hill B, Dean R, Pohlman B, Smith MR, Jagadeesh D. Impact of Comorbidities on Outcomes of Elderly Patients with Diffuse Large B-cell Lymphoma. American Journal of Hematology. PMID 28612386 DOI: 10.1002/ajh.24819  0.071
2016 Hong S, Rybicki L, Abounader D, Bolwell BJ, Dean R, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS. Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26995694 DOI: 10.1016/j.bbmt.2016.03.011  0.071
1992 Hill BT, Shellard SA, Hosking LK, Dempke WCM, Fichtinger-Schepman AMJ, Tone T, Scanlon KJ, Whelan RDH. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate Cancer Research. 52: 3110-3118. PMID 1591724  0.07
2017 Winter A, Rybicki L, Shah SN, Jagadeesh D, Gerds AT, Hamilton BK, Liu H, Dean R, Sobecks R, Pohlman B, Smith M, Kalaycio M, Bolwell BJ, Majhail NS, Hill BT. Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leukemia & Lymphoma. 1-7. PMID 28853617 DOI: 10.1080/10428194.2017.1369065  0.07
2020 Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, JaglowskiMPH S, Hill B, Danilov AV. Comorbidities Predict Inferior Survival in Patients receiving Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma: A Multicenter Analysis. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 33002640 DOI: 10.1016/j.bbmt.2020.09.028  0.07
2012 Hamilton BK, Haddad H, Dabney J, Bolwell BJ, Rybicki L, McLellan L, Foster L, Cooper M, Tench S, Kalaycio M, Sobecks R, Dean RM, Hill BT, Duong HK, Copelan EA. Superior Quality of Life Scores in Patients Over 60 Years of Age in Allogeneic Hematopoietic Cell Transplant. Blood. 120: 3068-3068. DOI: 10.1182/blood.v120.21.3068.3068  0.07
2010 Hill BT, Rybicki L, Bolwell BJ, Dean R, Pohlman B, Tench S, Sobecks R, Andresen S, Copelan EA, Kalaycio M. Older Patients with AML Undergoing Matched Related Allogeneic Transplantation Have Significantly Older Donors but Equivalent Survival as Patients Receiving Unrelated Donor Transplants Blood. 116: 2356-2356. DOI: 10.1182/blood.v116.21.2356.2356  0.07
2017 Casasnovas R, Westin J, Thieblemont C, Zijlstra J, Hill B, De La Cruz Vicente F, Choquet S, Caimi P, Kaplan J, Canales M, Kuruvilla J, Follows G, van den Neste E, Meade J, Wrigley B, et al. A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) Hematological Oncology. 35: 191-192. DOI: 10.1002/hon.2438_53  0.07
1996 Hill BT. Evidence of differential regulation of P-glycoprotein overexpression in drug-resistant tumour cells selected by exposure to X-irradiation as opposed to antitumour drugs Onkologie. 19: 6-9.  0.07
2012 Hamilton BK, Bolwell BJ, Rybicki L, Tench S, Kalaycio M, Andresen S, Dean RM, Sobecks R, Pohlman B, Hill BT, Hanna R, Duong HK, Copelan EA. Long Term Survival After High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation in Metastatic Breast Cancer. Blood. 120: 3072-3072. DOI: 10.1182/blood.v120.21.3072.3072  0.069
2004 Santelli-Rouvier C, Barret JM, Farrell CM, Sharples D, Hill BT, Barbe J. Synthesis of 9-acridinyl sulfur derivatives: sulfides, sulfoxides and sulfones. Comparison of their activity on tumour cells. European Journal of Medicinal Chemistry. 39: 1029-38. PMID 15571864 DOI: 10.1016/j.ejmech.2004.06.015  0.069
1988 Whelan R, Gibby E, Sheer D, Povey S, Hill BT. Characterization of a continuous cell line in culture established from a Krukenberg tumour of the ovary arising from a primary gastric adenocarcinoma. European Journal of Cancer & Clinical Oncology. 24: 1397-408. PMID 2846312 DOI: 10.1016/0277-5379(88)90328-8  0.069
2019 El-Asmar J, Rybicki L, Bolwell BJ, Kharfan-Dabaja MA, Dean R, Hamilton BK, Hanna R, Jagadeesh D, Kalaycio M, Pohlman B, Sobecks R, Hill BT, Majhail NS. Conditional Long-term Survival After Autologous Hematopoietic Cell Transplantation For Diffuse Large B-cell Lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31525493 DOI: 10.1016/j.bbmt.2019.09.012  0.069
2014 Lukenbill J, Hill B. Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients. Leukemia & Lymphoma. 56: 293-300. PMID 24813764 DOI: 10.3109/10428194.2014.910660  0.069
2017 William BM, Wang T, Haagenson MD, Fleischhauer K, Verneris M, Hsu KC, de Lima MJ, Fernandez-Viña M, Spellman SR, Lee SJ, Hill BT. Impact of Human Leukocyte Antigen (HLA) Alleles on Outcomes of Allogeneic Transplantation for B-Cell Non-Hodgkin Lymphomas: a Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29155319 DOI: 10.1016/J.Bbmt.2017.11.003  0.069
2015 Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, Hsi ED, Almasan A. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death & Disease. 6: e1593. PMID 25590803 DOI: 10.1038/Cddis.2014.525  0.068
2018 Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Pablo Alderuccio J, et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. British Journal of Haematology. PMID 30575016 DOI: 10.1111/bjh.15720  0.068
1998 Etievant C, Schambel P, Guminski Y, Barret JM, Imbert T, Hill BT. Requirements for P-glycoprotein recognition based on structure-activity relationships in the podophyllotoxin series. Anti-Cancer Drug Design. 13: 317-36. PMID 9627671  0.068
2013 Karol J, Rybicki L, Sweetenham J, Smith MR, Hill BT, Pohlman B, Jagadeesh D, Gazdick E, Fenner K, Maggiotto AL, Dean RM. Similar Incidence Of Febrile Neutropenia With Same-Day Versus Subsequent Day G-CSF Administration In Non-Hodgkin Lymphoma Patients Receiving R-CHOP Chemotherapy Blood. 122: 4357-4357. DOI: 10.1182/blood.V122.21.4357.4357  0.068
2019 Neelapu SS, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole O, Lin Y, Braunschweig I, Hill BT, Timmerman J, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, et al. 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Biology of Blood and Marrow Transplantation. 25: S65. DOI: 10.1016/J.Bbmt.2018.12.148  0.068
2020 Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, ... ... Hill BT, et al. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Advances. 4: 253-262. PMID 31945157 DOI: 10.1182/bloodadvances.2019000875  0.068
2018 Landsburg DJ, Hughes ME, Koike A, Bond DA, Maddocks KJ, Guo L, Winter AM, Hill BT, Ondrejka SL, Hsi ED, Dwivedy Nasta S, Svoboda J, Schuster SJ, Bogusz AM. Outcomes of Patients with Relapsed/Refractory Double Expressor B Cell Lymphoma As Defined By Multicenter Pathology Review Treated with Ibrutinib Monotherapy Blood. 132: 455-455. DOI: 10.1182/Blood-2018-99-117514  0.068
2019 Hill BT, Rybicki LA, Urban TA, Lucena M, Jagadeesh D, Gerds AT, Dean RM, Sobecks RM, Pohlman B, Bolwell B, Kalaycio ME, Hamilton BK, Copelan EA, Majhail NS. Therapeutic Dose Monitoring of Busulfan is Associated with a Reduction in Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31610237 DOI: 10.1016/j.bbmt.2019.09.033  0.067
2021 Chakraborty R, Hill BT, Majeed A, Majhail NS. Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies. Transplantation and Cellular Therapy. 27: 222-229. PMID 33928266 DOI: 10.1016/j.jtct.2020.10.002  0.067
2019 Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, et al. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800690. PMID 30615550 DOI: 10.1200/Jco.18.00690  0.067
2011 Lazaryan A, Sweetenham J, Rybicki L, Dean R, Pohlman B, Hill BT, Duong H, Sobecks R, Andresen S, Tench S, Kalaycio M, Bolwell BJ, Copelan EA. Prognostic Significance of Bone Marrow Involvement At Diagnosis and At the Time of Autologous Stem Cell Transplantation for Lymphoma Relapse, Blood. 118: 4122-4122. DOI: 10.1182/blood.v118.21.4122.4122  0.067
2018 Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, et al. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. American Journal of Hematology. PMID 30132965 DOI: 10.1002/ajh.25261  0.067
2021 Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, ... ... Hill BT, et al. Multi-Center Analysis of Practice Patterns and Outcomes of Younger and Older Patients with Mantle Cell Lymphoma in the Rituximab Era. American Journal of Hematology. PMID 34324220 DOI: 10.1002/ajh.26306  0.067
2021 Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, et al. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. Transplantation and Cellular Therapy. 27: 720-728. PMID 34452722 DOI: 10.1016/j.jtct.2021.03.001  0.067
2018 Smith SD, Gandhy S, Gopal AK, Reddy P, Shadman M, Till BG, Lynch RC, Kanan S, Cowan A, Low L, Hill BT. Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. PMID 30409719 DOI: 10.1016/j.clml.2018.10.006  0.067
2016 Hong S, Rybicki L, Abounader D, Dabney J, Dean RM, Gerds AT, Jagadeesh D, Lawrence C, Hamilton BK, Hill BT, Liu HK, Kalaycio M, Mclellan L, Pohlman B, Sobecks R, et al. Pre-Transplant Psychosocial Assessment and Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults Blood. 128: 3552-3552. DOI: 10.1182/blood.V128.22.3552.3552  0.067
2018 Rahman S, Rybicki L, Cober E, Dean RM, Hamilton BK, Jagadeesh D, Hill BT, Pohlman B, Sobecks R, Kalaycio M, Mossad S, Majhail NS. Early Infectious Complications after Autologous Hematopoietic Cell Transplantation (AHCT) for Lymphoma Blood. 132: 4755-4755. DOI: 10.1182/blood-2018-99-117758  0.066
2013 Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Barnett E, Marine J, et al. Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Blood. 122: 1630-1630. DOI: 10.1182/Blood.V122.21.1630.1630  0.066
2014 Hamilton BK, Rybicki L, Dabney J, McLellan L, Haddad H, Foster L, Abounader D, Kalaycio M, Sobecks R, Dean R, Duong H, Hill BT, Bolwell BJ, Copelan EA. Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 49: 1426-31. PMID 25068430 DOI: 10.1038/bmt.2014.166  0.066
2012 Lazaryan A, Copelan EA, Bejanyan N, Dean RM, Sobecks RM, Hill BT, Pohlman BL, Kalaycio ME, Bolwell BJ, Sweetenham JW. Association of prior rituximab exposure among patients undergoing autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma with inferior outcomes in males compared with females. Journal of Clinical Oncology. 30: 8055-8055. DOI: 10.1200/jco.2012.30.15_suppl.8055  0.066
2020 Hong S, Rybicki L, Corrigan D, Hamilton BK, Sobecks R, Kalaycio M, Gerds AT, Dean R, Hill B, Pohlman B, Jagadeesh D, Anwer F, Majhail NS. Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era. Hematology/Oncology and Stem Cell Therapy. PMID 33301747 DOI: 10.1016/j.hemonc.2020.11.006  0.066
2013 Hamilton BK, Tabarroki A, Elson P, Hasrouni E, Visconte V, Tench S, Kalaycio ME, Sekeres MA, Sobecks RM, Duong HK, Hill BT, Bolwell BJ, Copelan EA, Tiu RV. Impact of allogeneic hematopoietic stem cell transplant (HSCT) on patients harboring the spliceosome mutation SRSF2. Journal of Clinical Oncology. 31: 7008-7008. DOI: 10.1200/jco.2013.31.15_suppl.7008  0.066
2021 Shah J, Shacham S, Kauffman M, Daniele P, Tomaras D, Tremblay G, Casasnovas RO, Maerevoet M, Zijlstra J, Follows G, P Vermaat JS, Kalakonda N, Goy AH, Choquet S, Den Neste EV, ... Hill BT, et al. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. Future Oncology (London, England). PMID 33528286 DOI: 10.2217/fon-2020-0946  0.066
2014 Aronow ME, Hill BT, Singh AD. Orbital and adnexal lymphoma Clinical Ophthalmic Oncology: Orbital Tumors, Second Edition. 123-139. DOI: 10.1007/978-3-642-40492-4_12  0.066
2016 Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, et al. Phase 1 study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed or refractory chronic lymphocytic leukemia. Haematologica. PMID 27151992 DOI: 10.3324/Haematol.2015.140806  0.066
2022 Hu R, Wei W, Mian A, Gonter-Aubin K, Kabel C, Mato A, Stephens DM, Hanlon A, Khajavian S, Shadman M, Brander D, Madanat Y, Park JH, Tallman M, Pinilla-Ibarz J, ... Hill BT, et al. Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia at First Relapse. European Journal of Haematology. PMID 35043475 DOI: 10.1111/ejh.13744  0.066
2019 Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, ... ... Hill BT, et al. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. PMID 31568564 DOI: 10.1002/cncr.32526  0.066
2022 Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102370. PMID 35658525 DOI: 10.1200/JCO.21.02370  0.065
2022 Warren RV, Bar-Yoseph R, Hill B, Reilly D, Chiu A, Radom-Aizik S, Cooper DM, Tromberg BJ. Diffuse optical spectroscopic method for tissue and body composition assessment. Journal of Biomedical Optics. 27. PMID 35676754 DOI: 10.1117/1.JBO.27.6.065002  0.065
2016 Patil PD, Rybicki L, Abounader D, Liu HK, Hill BT, Dean R, Hamilton BK, Gerds AT, Pohlman B, Sobecks R, Bolwell BJ, Kalaycio M, Majhail NS, Jagadeesh D. Higher Hematopoietic Cell Transplant Comorbidity Index (HCT-CI) Is Associated with Poor Psychosocial Health Pre-Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients Blood. 128: 4791-4791. DOI: 10.1182/blood.V128.22.4791.4791  0.065
2012 Collie AMB, Nolling J, Lin JJ, Hill BT, Radivoyevitch T, Kong L, Hsi ED. Molecular Subtype Characterization of Formalin-Fixed, Paraffin-Embedded Diffuse Large B-Cell Lymphoma Samples on the Iceplex® System. Blood. 120: 2705-2705. DOI: 10.1182/blood.V120.21.2705.2705  0.065
2019 Byrne M, Oluwole OO, Savani B, Majhail NS, Hill BT, Locke FL. Understanding and managing large B cell lymphoma relapses after CAR T cell therapy. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31279751 DOI: 10.1016/j.bbmt.2019.06.036  0.065
2014 Hill BT, Smith MR, Mears J, Healy A, Shelley M, Wyckhouse J, Kakish J, Jagadeesh D, Dean RM, Pohlman B, Smith SD. Phase I Trial of Bortezomib and Everolimus in Relapsed/Refractory Non-Hodgkin Lymphoma Blood. 124: 4482-4482. DOI: 10.1182/blood.v124.21.4482.4482  0.065
2020 Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Peng W, et al. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study Biology of Blood and Marrow Transplantation. 26: S1. DOI: 10.1016/J.BBMT.2019.12.135  0.065
2016 Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro J, ... ... Hill BT, et al. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27660167 DOI: 10.1016/J.Bbmt.2016.09.013  0.065
2015 Fu S, Rybicki L, Abounader D, Andresen S, Bolwell BJ, Dean R, Gerds A, Hamilton BK, Hanna R, Hill BT, Jagadeesh D, Kalaycio ME, Liu HD, Pohlman B, Sobecks RM, et al. Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. PMID 26191953 DOI: 10.1038/bmt.2015.166  0.065
2014 Jagadeesh D, Hooda S, Fenner KB, Rybicki L, Dean RM, Pohlman B, Hill BT, Smith MR. Post Transplant Lymphoproliferative Disorders (PTLD) after Solid Organ Transplant: Cleveland Clinic Experience Blood. 124: 3008-3008. DOI: 10.1182/blood.V124.21.3008.3008  0.065
2019 Zhong C, Gragert L, Maiers M, Hill BT, Garcia-Gomez J, Gendzekhadze K, Senitzer D, Song J, Weisenburger D, Goldstein L, Wang SS. The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population. Leukemia & Lymphoma. 1-10. PMID 31215275 DOI: 10.1080/10428194.2019.1617858  0.065
1994 Hill BT, Shellard SA, Fichtinger-Schepman AM, Schmoll HJ, Harstrick A. Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. Anti-Cancer Drugs. 5: 321-8. PMID 7919457  0.064
1998 Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemotherapy and Pharmacology. 41: 437-47. PMID 9554586 DOI: 10.1007/s002800050764  0.064
2021 Sawalha Y, Radivoyevitch T, Jia X, Tullio K, Dean RM, Pohlman B, Hill BT, Kalaycio M, Majhail NS, Jagadeesh D. The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. Leukemia & Lymphoma. 1-9. PMID 34521300 DOI: 10.1080/10428194.2021.1978085  0.064
1990 Hosking LK, Whelan RDH, Shellard SA, Bedford P, Hill BT. An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines Biochemical Pharmacology. 40: 1833-1842. PMID 2242017 DOI: 10.1016/0006-2952(90)90364-Q  0.064
2016 Sawalha Y, Rouphail B, Jia X, Dean RM, Hill BT, Jagadeesh D, Pohlman BL, Smith MR. Is rituximab sub-optimally dosed in indolent B cell lymphoma? British Journal of Haematology. PMID 27136331 DOI: 10.1111/bjh.14114  0.064
2021 Mian A, Andrapalliyal N, Weathers AL, Pohlman B, Hill BT. Late occurrence of progressive multifocal leukoencephalopathy after anti-CD19 chimeric antigen receptor T-cell therapy. European Journal of Haematology. PMID 33459429 DOI: 10.1111/ejh.13583  0.064
2019 Spiegel JY, Dahiya S, Jain MD, Nastoupil LJ, Ghobadi A, Lin Y, Lunning MA, Reagan PM, McGuirk J, Deol A, Munoz J, Locke FL, Neelapu SS, Tamaresis JS, Rapoport A, ... ... Hill BT, et al. Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the U.S. Lymphoma CAR-T Consortium. Journal of Clinical Oncology. 37: 7517-7517. DOI: 10.1200/Jco.2019.37.15_Suppl.7517  0.063
2014 Hamilton BK, Rybicki L, Abounader DM, Dabney J, Dean RM, Duong HK, Hill BT, Gerds A, Jagadeesh D, Kalaycio ME, Lawrence C, McLellan L, Pohlman B, Sobecks RM, Bolwell BJ, et al. Prognostic Significance of Quality of Life in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation Blood. 124: 2637-2637. DOI: 10.1182/blood.v124.21.2637.2637  0.063
2021 Maerevoet M, Zijlstra JM, Follows G, Casasnovas RO, Vermaat JSP, Kalakonda N, Goy A, Choquet S, Van Den Neste E, Hill B, Thieblemont C, Cavallo F, De la Cruz F, Kuruvilla J, Hamad N, et al. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. Journal of Hematology & Oncology. 14: 111. PMID 34271963 DOI: 10.1186/s13045-021-01122-1  0.063
2019 Singer S, Dean R, Zhao Q, Sharma N, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, ... ... Hill B, et al. BEAM Vs BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN'S LYMPHOMA. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30716453 DOI: 10.1016/j.bbmt.2019.01.032  0.063
2007 Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L, Odenike O, Pursell KJ, Larson RA, Stock W, van Besien K. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leukemia & Lymphoma. 48: 1799-805. PMID 17786717 DOI: 10.1080/10428190701534390  0.063
2021 Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplantation. PMID 34413469 DOI: 10.1038/s41409-021-01288-9  0.063
2019 Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, et al. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Advances. 3: 1568-1573. PMID 31101647 DOI: 10.1182/bloodadvances.2019000180  0.063
2019 Kalakonda N, Cavallo F, Follows G, Goy A, Vermaat JS, Casasnovas O, Lavee O, Maerevoet M, Zijlstra J, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, et al. A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Lymphoma Myeloma and Leukemia. 19: S248-S249. DOI: 10.1016/J.Clml.2019.07.153  0.063
2019 Kalakonda N, Cavallo F, Follows G, Goy A, Vermaat J, Casasnovas O, Lavee O, Maerevoet M, Zijlstra J, Bakshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, et al. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) Hematological Oncology. 37: 62-64. DOI: 10.1002/HON.31_2629  0.063
2019 Kapoor I, Li Y, Sharma A, Zhu H, Bodo J, Xu W, Hsi ED, Hill BT, Almasan A. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death & Disease. 10: 924. PMID 31801949 DOI: 10.1038/S41419-019-2158-0  0.063
2016 Patel SS, Rybicki L, Abounader D, Bolwell BJ, Dean R, Liu HK, Gerds AT, Hanna R, Hill BT, Jagadeesh D, Kalaycio M, Pohlman B, Sobecks R, Majhail NS, Hamilton BK. Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT) Blood. 128: 4666-4666. DOI: 10.1182/blood.V128.22.4666.4666  0.062
2014 Sun D, Hill BT, Rybicki L, Rouphail B, Dean RM, Jagadeesh D, Gerds AT, Hamilton BK, Sobecks RM, Duong HK, Andresen S, Majhail NS, Pohlman B, Kalaycio ME, Bolwell BJ, et al. Efficacy of Standard Dose R-CHOP Alternating with R-HiDAC Followed By ASCT As Initial Therapy of Mantle Cell Lymphoma: Cleveland Clinic Experience Blood. 124: 1730-1730. DOI: 10.1182/blood.V124.21.1730.1730  0.062
2019 Awada H, Mahfouz RZ, Durrani J, Kishtagari A, Jagadeesh D, Lichtin, MD A, Hill BT, Hamilton BK, Carraway HE, Majhail NS, Sobecks R, Visconte V, Kalaycio M, Sekeres MA, et al. Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation Blood. 134: 1226-1226. DOI: 10.1182/blood-2019-130167  0.062
2016 Mato AR, Hill BT, Lamanna N, Barr P, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson B, Zent CS, Pu JJ, Kiselev P, Bachow SH, Winter AM, Cruz A, et al. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients Blood. 128: 4400-4400. DOI: 10.1182/blood.V128.22.4400.4400  0.062
1992 Dempke WCM, Shellard SA, Hosking LK, Fichtinger-Schepman AMJ, Hill BT. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro Carcinogenesis. 13: 1209-1215. PMID 1638688  0.062
1993 Shellard SA, Fichtinger-Schepman AMJ, Lazo JS, Hill BT. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines Anti-Cancer Drugs. 4: 491-500. PMID 8400352  0.062
1992 Dempke WCM, Hosking LK, Hill BT. Expression of collateral sensitivity to cisplatin, methotrexate, and fluorouracil in a human ovarian carcinoma cell line following exposure to fractionated x-irradiation in vitro Seminars in Oncology. 19: 66-72. PMID 1557659  0.062
2016 Hill BT, Rybicki L, Carlstrom KD, Jagadeesh D, Gerds A, Hamilton B, Liu H, Dean R, Sobecks R, Pohlman B, Andresen S, Kalaycio M, Bolwell BJ, Majhail NS. Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide (Bu/Cy/E) Produces Comparable Outcomes to 4-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation (ASCT). Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27343718 DOI: 10.1016/j.bbmt.2016.06.011  0.062
2018 Maerevoet M, Vermaat J, Canales MA, Casasnovas R, Van Den Neste E, Goy A, Hill BT, Thieblemont C, De La Cruz MDF, Cavallo F, Follows G, Choquet S, Gurion R, Bouabdallah R, Jaeger U, et al. Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study Blood. 132: 1677-1677. DOI: 10.1182/BLOOD-2018-99-116868  0.062
1990 Hill BT, Whelan RDH, Hosking LK, Bedford P, Dempke WCM, Shellard SA. Differential expression of drug resistance following in vitro exposure of human tumour cell lines to fractionated X-irradiation Cancer Treatment Reviews. 17: 21-26. PMID 1982640 DOI: 10.1016/0305-7372(90)90012-5  0.061
2019 Landsburg DJ, Hughes ME, Koike A, Bond D, Maddocks KJ, Guo L, Winter AM, Hill BT, Ondrejka SL, Hsi ED, Nasta SD, Svoboda J, Schuster SJ, Bogusz AM. Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. Blood Advances. 3: 132-135. PMID 30651281 DOI: 10.1182/Bloodadvances.2018026401  0.061
1993 Hill BT. Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro Cytotechnology. 12: 265-288. PMID 7765329 DOI: 10.1007/BF00744668  0.061
2018 Nastoupil LJ, Jain MD, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning MA, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Sehgal AR, Goy A, Hill BT, et al. Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience Blood. 132: 91-91. DOI: 10.1182/BLOOD-2018-99-114152  0.061
1994 Braakhuis BJM, Hill BT, Dietel M, Kelland LR, Aapro MS, Zoli W, Lelieveld P. In vitro antiproliferative activity of docetaxel (Taxotere®), paclitaxel (Taxol®) and cisplatin against human tumour and normal bone marrow cells Anticancer Research. 14: 205-208. PMID 7909419  0.061
2001 Etiévant C, Kruczynski A, Barret JM, Tait AS, Kavallaris M, Hill BT. Markedly diminished drug resistance-inducing properties of vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemotherapy and Pharmacology. 48: 62-70. PMID 11488526 DOI: 10.1007/s002800100275  0.061
2003 Shnyder SD, Cooper PA, Gyselinck N, Hill BT, Double JA, Bibby MC. Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model. Anticancer Research. 23: 4815-20. PMID 14981930  0.06
2015 Hamilton BK, Rybicki L, Sekeres M, Kalaycio M, Hanna R, Sobecks R, Dean R, Duong H, Hill BT, Bolwell B, Copelan E. Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites. Bone Marrow Transplantation. 50: 834-9. PMID 25798671 DOI: 10.1038/bmt.2015.44  0.06
1993 McClean S, Hill BT. Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells European Journal of Cancer. 29: 2243-2248. PMID 7906532 DOI: 10.1016/0959-8049(93)90215-2  0.06
2016 Patel SS, Rybicki L, Abounader D, Dumont C, Bolwell BJ, Dean R, Figueroa P, Hanna R, Liu HK, Gerds AT, Hill BT, Jagadeesh D, Kalaycio M, Ricci K, Sobecks R, et al. Prognostic Effect of Bone Marrow (BM) and Peripheral Blood Stem Cell (PBSC) Donor Cell Subsets on Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Blood. 128: 660-660. DOI: 10.1182/blood.v128.22.660.660  0.06
1991 Shellard SA, Hosking LK, Hill BT. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro Cancer Research. 51: 4557-4564. PMID 1873800  0.06
1994 Hill BT, Price LA. Lack of survival advantage in patients with advanced squamous cell carcinomas of the oral cavity receiving neoadjuvant chemotherapy prior to local therapy, despite achieving an initial high clinical complete remission rate. American Journal of Clinical Oncology. 17: 1-5. PMID 8310999  0.06
2015 Schneider KM, Banks PM, Collie AM, Lanigan CP, Manilich E, Durkin LM, Hill BT, Hsi ED. Dual Expression of MYC and BCL2 Proteins Predicts Worse Outcomes in Diffuse Large B-Cell Lymphoma. Leukemia & Lymphoma. 1-23. PMID 26421520 DOI: 10.3109/10428194.2015.1101099  0.06
2016 Radivoyevitch T, Sachs RK, Gale RP, Smith MR, Hill BT. Ionizing radiation exposures in treatments of solid neoplasms are not associated with subsequent increased risks of chronic lymphocytic leukemia. Leukemia Research. 43: 9-12. PMID 26922774 DOI: 10.1016/J.Leukres.2016.02.008  0.059
1987 Hill BT. in vitro screening of new drugs and analogues-specificity and selectivity Cancer Treatment Reviews. 14: 197-202. PMID 3326663 DOI: 10.1016/0305-7372(87)90008-9  0.059
2015 Hill BT, Kalaycio M. Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. Oncotargets and Therapy. 8: 2391-7. PMID 26366093 DOI: 10.2147/OTT.S68770  0.059
2019 Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, et al. Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. British Journal of Haematology. PMID 31044423 DOI: 10.1111/Bjh.15923  0.059
2017 Sawalha Y, Hill BT, Rybicki LA, Sun D, Dean RM, Jagadeesh D, Hamilton BK, Gerds AT, Sobecks RM, Andresen S, Liu HK, Majhail NS, Pohlman B, Kalaycio ME, Bolwell BJ, et al. Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. Clinical Lymphoma, Myeloma & Leukemia. PMID 29208403 DOI: 10.1016/j.clml.2017.11.002  0.059
2016 Allen JM, Ruano Mendez AL, Rybicki LA, Jagadeesh D, Dean RM, Pohlman BL, Smith MR, Hsi ED, Hill BT. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma treated with R-ICE based on dual expression of MYC and BCL2. Journal of Clinical Oncology. 34: e19043-e19043. DOI: 10.1200/jco.2016.34.15_suppl.e19043  0.059
2020 Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. The New England Journal of Medicine. 382: 1331-1342. PMID 32242358 DOI: 10.1056/Nejmoa1914347  0.059
2014 Gragert L, Fingerson S, Albrecht M, Maiers M, Kalaycio M, Hill BT. Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. Blood. 124: 2657-65. PMID 25232063 DOI: 10.1182/blood-2014-02-558767  0.059
2013 Robak T, Hellman A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Stromatt S, Jaeger U. Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) Blood. 122: 2860-2860. DOI: 10.1182/blood.V122.21.2860.2860  0.059
1993 McClean S, Whelan RDH, Hosking LK, Hodges GM, Thompson FH, Meyers MB, Schuurhuis GJ, Hill BT. Characterization of the P-glycoprotein over-expressing drug resistance phenotype exhibited by Chinese hamster ovary cells following their in-vitro exposure to fractionated X-irradiation Bba - Molecular Cell Research. 1177: 117-126. PMID 8098957 DOI: 10.1016/0167-4889(93)90030-S  0.059
2016 Jagadeesh D, Rybicki L, Abounader D, Liu H, Dean RM, Hill BT, Sobecks RM, Gerds A, Hamilton BK, Pohlman B, Kalaycio ME, Bolwell B, Majhail NS. Autologous Stem Cell Transplantation (ASCT) Is Effective Therapy for Older Patients with Non-Hodgkin's Lymphoma (NHL) Biology of Blood and Marrow Transplantation. 22: S224-S225. DOI: 10.1016/j.bbmt.2015.11.628  0.059
2014 Turakhia SK, Hill BT, Dufresne SD, Nakashima MO, Cotta CV. Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics. American Journal of Clinical Pathology. 142: 339-46. PMID 25125624 DOI: 10.1309/Ajcpbwvhtf7Rrsa4  0.058
2018 Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr P, Lansigan F, Cheson B, Singavi AK, Yazdy M, Shah NN, Allan JN, Bhavsar EB, et al. Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients Blood. 132: 3142-3142. DOI: 10.1182/blood-2018-99-114840  0.058
2017 Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, et al. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer. PMID 29125192 DOI: 10.1002/cncr.31114  0.058
2021 Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, ... ... Hill BT, et al. Intensive Induction Regimens after Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated with Improved Survival. European Journal of Haematology. PMID 33973276 DOI: 10.1111/ejh.13649  0.058
2021 Schuster M, Zijlstra J, Casasnovas RO, Vermaat JSP, Kalakonda N, Goy A, Choquet S, Neste EVD, Hill B, Thieblemont C, Cavallo F, De la Cruz F, Kuruvilla J, Hamad N, Jaeger U, et al. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. Clinical Lymphoma, Myeloma & Leukemia. PMID 35078739 DOI: 10.1016/j.clml.2021.12.016  0.058
1994 Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M, Fichtinger-Schepman AMJ, Shellard SA. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients European Journal of Cancer. 30: 832-837. PMID 7917544 DOI: 10.1016/0959-8049(94)90301-8  0.058
2019 Hill BT, Rybicki L, Urban TA, Lucerna M, Jagadeesh D, Gerds AT, Dean RM, Sobecks RM, Pohlman B, Bolwell B, Kalaycio ME, Hamilton BK, Copelan EA, Majhail NS. Pharmacokinetic-Guided Therapeutic Dose Monitoring (TDM) of Busulfan Reduces Relapse of Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplantation (ASCT) Biology of Blood and Marrow Transplantation. 25: S31-S32. DOI: 10.1016/j.bbmt.2018.12.103  0.058
2016 Madanat YF, Smith MR, Almasan A, Hill BT. Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. Blood and Lymphatic Cancer : Targets and Therapy. 6: 1-6. PMID 27375364 DOI: 10.2147/BLCTT.S73530  0.058
1986 Hill BT. Resistance of mammalian tumour cells to anticancer drugs: Mechanisms and concepts relating specifically to methotrexate and vincristine Journal of Antimicrobial Chemotherapy. 18: 61-73. PMID 3793664  0.058
2020 Smith SD, Lopedote P, Samara Y, Mei M, Herrera AF, Winter AM, Hill BT, Shadman M, Ujjani C, Lynch RC, Jacobson CA, Kim AI, Caimi P, Milano F, Gopal AK. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. Clinical Lymphoma, Myeloma & Leukemia. PMID 33431309 DOI: 10.1016/j.clml.2020.12.013  0.058
1992 Dempke WCM, Whelan RDH, Hill BT. Expression of resistance to etoposide and vincristine in vitro and in vivo after X-irradiation of ovarian tumor cells Anti-Cancer Drugs. 3: 395-399. PMID 1421436  0.057
2012 Hamilton BK, Haddad H, Copelan EA, Rybicki L, Tench S, Yurch M, Bolwell BJ, Hanna R, Sobecks R, Dean RM, Duong HK, Hill BT, Kalaycio M. Omission of Methotrexate Doses Due to Toxicity Does Not Influence the Incidence of Gvhd, Relapse, or Survival Blood. 120: 4189-4189. DOI: 10.1182/blood.v120.21.4189.4189  0.057
2019 Winter AM, Wei W, Ayers EC, Landsburg DJ, Raya S, Kahl BS, Rogers A, Maddocks KJ, Khan M, Kittai AS, Danilov A, Ujjani CS, Lynch RC, Nastoupil LJ, Becnel MR, ... ... Hill BT, et al. Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis Blood. 134: 3982-3982. DOI: 10.1182/blood-2019-124783  0.057
2019 Caimi P, Jagadeesh D, Boughan K, Dean R, Cooper B, Pohlman B, Gallogly M, Ondrejka S, Moore E, Oduro K, Hsi E, de Lima M, Hill B. SAFETY AND EFFICACY OF VENETOCLAX COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (VICER) FOR TREATMENT OF RELAPSED DLBCL: FINAL RESULTS FROM THE PHASE 1TRIAL Hematological Oncology. 37: 329-330. DOI: 10.1002/HON.141_2630  0.057
2021 Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski MC, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, et al. Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy. Blood Advances. PMID 34516611 DOI: 10.1182/bloodadvances.2021004765  0.057
1994 Shellard SA, Hosking LK, Hill BT. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line. Biochemical Pharmacology. 47: 775-9. PMID 8135853 DOI: 10.1016/0006-2952(94)90476-6  0.057
1987 Spittle MF, Hill BT, Ostrowski MJ, Macrae KD, Bates TD, Martin WMC, Nicol NT, Edelstyn GA. A randomized, prospective, comparative, multicentre trial of a single combination versus alternating combinations of antitumour drugs in advanced breast cancer European Journal of Cancer and Clinical Oncology. 23: 1155-1162. PMID 3308483 DOI: 10.1016/0277-5379(87)90149-0  0.057
2020 Hong S, Rybicki L, Corrigan D, Hamilton BK, Sobecks RM, Kalaycio ME, Dean RM, Hill BT, Pohlman B, Jagadeesh D, Anwer F, Majhail NS. Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome in the Contemporary Era Biology of Blood and Marrow Transplantation. 26: S117-S118. DOI: 10.1016/j.bbmt.2019.12.629  0.057
2018 Patel SS, Rybicki LA, Corrigan D, Bolwell B, Dean R, Liu H, Gerds AT, Hanna R, Hill B, Jagadeesh D, Kalaycio M, Pohlman B, Sobecks R, Majhail NS, Hamilton BK. Prognostic Factors for Mortality among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29369800 DOI: 10.1016/j.bbmt.2018.01.016  0.056
2010 Hill B, Rybicki L, Smith S, Dean R, Kalaycio M, Pohlman B, Sweetenham J, Tench S, Sobecks R, Andresen S, Copelan E, Bolwell B. Treatment With Hyper-CVAD Results In Poor Mobilization Of Peripheral Blood Stem Cells In Patients With Mantle Cell Lymphoma Biology of Blood and Marrow Transplantation. 16: S202. DOI: 10.1016/j.bbmt.2009.12.151  0.056
2019 Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe V, Antin JH, Sorror M, Shadman M, Press OW, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, ... ... Hill BT, et al. Prognostic score and cytogenetic risk classification for chronic lymphocytic leukemia patients: Center for International Blood and Marrow Transplant Research report. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31253630 DOI: 10.1158/1078-0432.Ccr-18-3988  0.056
2012 Hamilton BK, Tabarroki A, Visconte V, Hasrouni E, Makishima H, Tench S, Kalaycio M, Sekeres MA, Sobecks R, Duong HK, Hill BT, Maciejewski JP, Bolwell BJ, Copelan EA, Tiu RV. Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Blood. 120: 1973-1973. DOI: 10.1182/blood.V120.21.1973.1973  0.056
1987 Bellamy AS, Whelan RDH, Lock RB, Hill BT. Effects of fractionated x-irradiation on subsequent response to acute x-irradiation in two human tumour cell lines in vitro International Journal of Radiation Biology. 51: 681-691. PMID 3495512 DOI: 10.1080/09553008414552211  0.056
2022 Baidoun F, Moustafa MA, Tun HW, Hill BT. Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study. Clinical Lymphoma, Myeloma & Leukemia. PMID 35110006 DOI: 10.1016/j.clml.2022.01.006  0.056
2019 Woyach J, Ruppert AS, Perez G, Booth AM, Feldman D, Dib EG, Jatoi A, Le-Rademacher J, Heerema NA, Lozanski G, Little R, Ding W, Hill BT, Stone RM, Mandrekar SJ, et al. Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) Blood. 134: 1751-1751. DOI: 10.1182/Blood-2019-127102  0.056
2019 Jain MD, Jacobs MT, Nastoupil LJ, Spiegel JY, Feng G, Lin Y, Lunning MA, Dahiya S, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Goy A, Hill BT, et al. Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium Blood. 134: 245-245. DOI: 10.1182/blood-2019-129624  0.056
1986 Hill BT, Whelan RDH. Spirogermanium - A novel antitumour agent expressing a lack of cross-resistance in vitro with a range of 'standard' antitumour drugs Investigational New Drugs. 4: 359-365. PMID 3583643 DOI: 10.1007/BF00173508  0.056
2014 Tavadze M, Rybicki L, Mossad S, Avery R, Yurch M, Pohlman B, Duong H, Dean R, Hill B, Andresen S, Hanna R, Majhail N, Copelan E, Bolwell B, Kalaycio M, et al. Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 49: 1310-6. PMID 25111516 DOI: 10.1038/bmt.2014.150  0.056
2010 Hill BT, Bolwell BJ, Rybicki L, Dean R, Kalaycio M, Pohlman B, Tench S, Sobecks R, Andresen S, Copelan E. Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 1738-46. PMID 20558313 DOI: 10.1016/j.bbmt.2010.06.009  0.056
2022 Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, et al. Real-world Evidence of Axicabtagene Ciloleucel for the Treatment of Large B-Cell Lymphoma in the United States. Transplantation and Cellular Therapy. PMID 35609867 DOI: 10.1016/j.jtct.2022.05.026  0.056
2020 Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, et al. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 185-217. PMID 32023533 DOI: 10.6004/Jnccn.2020.0006  0.055
2018 Patel SS, Rybicki LA, Corrigan D, Dumont C, Bolwell B, Dean R, Figueroa P, Hanna R, Liu H, Gerds AT, Hill B, Jagadeesh D, Kalaycio M, Pohlman B, Ricci K, et al. Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. PMID 30375493 DOI: 10.1038/s41409-018-0380-5  0.055
2013 GRAGERT L, DiPrima S, Albrecht M, Maiers M, Kalaycio M, Hill BT. HLA Is a Determinant Of The Ethnic Predisposition Of Chronic Lymphocytic Leukemia Blood. 122: 1620-1620. DOI: 10.1182/blood.V122.21.1620.1620  0.055
2016 Caimi PF, Hill BT, Hsi ED, Smith MR. Clinical approach to diffuse large B cell lymphoma. Blood Reviews. PMID 27596109 DOI: 10.1016/j.blre.2016.06.003  0.055
1990 Hill BT, Shellard SA, Hosking LK, Fichtinger-Schepman AMJ, Bedford P. Enhanced dna repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation International Journal of Radiation Oncology, Biology, Physics. 19: 75-83. PMID 2380098 DOI: 10.1016/0360-3016(90)90137-9  0.055
1991 Hill BT, Whelan RDH, Hosking LK, Shellard SA, Hinds MD, Mayes J, Zwelling LA. A lack of detectable modification of topoisomerase II activity in a series of human tumor cell lines expressing only low levels of etoposide resistance International Journal of Cancer. 47: 899-902. PMID 1849124  0.055
2020 Ujjani C, Mato A, Hill BT, Allan JN, Lansigan F, Jacobs R, Skarbnik A, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, et al. The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. Blood and Lymphatic Cancer : Targets and Therapy. 10: 1-5. PMID 32943973 DOI: 10.2147/BLCTT.S262592  0.055
2007 Fliszar KA, Hill BT, Foster N. Predicting human drug pharmacokinetics from in vitro permeability using an absorption-disposition model. Journal of Pharmaceutical Sciences. 96: 2161-70. PMID 17387695 DOI: 10.1002/Jps.20866  0.055
2016 Hong S, Valent J, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill B, Kalaycio ME, Pohlman B, Reu F, Samaras C, Sobecks R, et al. Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy. Bone Marrow Transplantation. PMID 26726941 DOI: 10.1038/bmt.2015.326  0.055
2018 Kothari SK, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess BT, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, ... ... Hill BT, et al. Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers Blood. 132: 451-451. DOI: 10.1182/BLOOD-2018-99-111530  0.055
2021 Casasnovas RO, Follows G, Zijlstra JM, Vermaat JSP, Kalakonda N, Choquet S, Neste EVD, Hill B, Thieblemont C, Cavallo F, la Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi PF, et al. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. Clinical Lymphoma, Myeloma & Leukemia. PMID 34493477 DOI: 10.1016/j.clml.2021.07.017  0.055
2019 Sharrett J, Shah C, Murphy E, Garcia A, Jagadeesh D, Dean R, Hill B, Pohlman B, Cherian S. Treatment Outcomes and Patterns of Failure in High Grade Lymphoma of the Thyroid Following Combined Modality Therapy: Single Institution Series International Journal of Radiation Oncology*Biology*Physics. 105: E474-E475. DOI: 10.1016/j.ijrobp.2019.06.1453  0.055
1988 Lock RB, Hill BT. Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines International Journal of Cancer. 42: 373-381. PMID 3417366  0.055
2002 Kruczynski A, Etiévant C, Perrin D, Chansard N, Duflos A, Hill BT. Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. British Journal of Cancer. 86: 143-50. PMID 11857026 DOI: 10.1038/sj.bjc.6600025  0.055
2013 Duong HK, Bates D, Rybicki LA, Kalaycio M, Steven A, Sobecks R, Gallagher L, Dean RM, Hill BT, Abounader DM, Yurch M, Ferraro C, Tench S, Cherni K, Green G, et al. A Randomized Study Of Music Therapy In Patients Undergoing Autologous Stem Cell Transplant: Decrease In Narcotic Medication Use For Pain Control Blood. 122: 1693-1693. DOI: 10.1182/blood.v122.21.1693.1693  0.055
2016 Saygin C, Jia X, Hill BT, Dean RM, Patel B, Pohlman B, Smith MR, Jagadeesh D. IPI, Comorbidity Index, Hospitalization for Treatment-Related Adverse Events Are Predictors for Outcome in Elderly Diffuse Large B Cell Lymphoma Patients Blood. 128: 1860-1860. DOI: 10.1182/blood.v128.22.1860.1860  0.055
2019 Urban TA, Lucena M, Gaffney K, Dean RM, Gerds AT, Hamilton BK, Jagadeesh D, Kalaycio ME, Pohlman B, Sobecks RM, Hill BT, Rybicki L, Majhail NS. Comparison of the Tolerability of Busulfan, Cyclophosphamide, Etoposide (BuCyVP) Versus Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) for Autologous Hematopoietic Cell Transplant (AHCT) in Hodgkin Lymphoma Biology of Blood and Marrow Transplantation. 25: S277-S278. DOI: 10.1016/j.bbmt.2018.12.344  0.055
2020 Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Sarraf Yazdy M, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, et al. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32198151 DOI: 10.1158/1078-0432.Ccr-19-3815  0.055
1990 Hill BT. Modulation of antitumour drug resistance: experimental laboratory data and results of clinical evaluation Cancer Treatment Reviews. 17: 197-202. PMID 1980233 DOI: 10.1016/0305-7372(90)90047-J  0.055
2016 Landsburg DJ, Reddy N, Howlett C, Feldman T, Mato AR, Kaplan JB, Behdad A, Petrich AM, Maly J, Blum K, Chavez JC, Li S, Medeiros LJ, Falkiewicz MK, Hill BT, et al. Benefit of Consolidative Autologous Stem Cell Transplantation in First Complete Remission for Patients with Double Hit Lymphoma Appears Dependent on Induction Regimen Intensity Blood. 128: 3455-3455. DOI: 10.1182/blood.V128.22.3455.3455  0.054
2005 Hill BT, Skowronski J. Human N-myristoyltransferases form stable complexes with lentiviral nef and other viral and cellular substrate proteins. Journal of Virology. 79: 1133-41. PMID 15613341 DOI: 10.1128/Jvi.79.2.1133-1141.2005  0.054
2009 Hill BT, Bolwell BJ, Rybicki L, Dean R, Kalaycio M, Pohlman B, Tench S, Sobecks R. Myeloablative Second Transplants Are Associated with High Non-Relapse Mortality and Poorer Survival Than Non-Myeloablative Second Transplants. Blood. 114: 3323-3323. DOI: 10.1182/blood.v114.22.3323.3323  0.054
2019 Gordon MJ, Kaempf A, Sitlinger A, Salous T, Alqahtani H, Churnetski MC, Wisniewski P, Rivera XI, Patel K, Persky DO, Cohen JB, Choi MY, Hill BT, Shadman M, Stephens DM, et al. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT) Blood. 134: 4286-4286. DOI: 10.1182/blood-2019-124631  0.054
2015 Pore D, Bodo J, Danda A, Yan D, Phillips JG, Lindner D, Hill BT, Smith MR, Hsi ED, Gupta N. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma. Leukemia. PMID 25801911 DOI: 10.1038/leu.2015.86  0.054
2013 Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, Almasan A. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. Cell Death & Disease. 4: e628. PMID 23681223 DOI: 10.1038/Cddis.2013.155  0.054
2015 Hamilton BK, Rybicki L, Haddad H, Abounader D, Yurch M, Majhail NS, Hanna R, Sobecks R, Dean R, Liu H, Hill B, Copelan E, Bolwell B, Kalaycio M. Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study. Blood Cancer Journal. 5: e344. PMID 26314986 DOI: 10.1038/bcj.2015.70  0.054
2000 Hill BT, Perrin D, Kruczynski A. Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited. Critical Reviews in Oncology/Hematology. 33: 7-23. PMID 10714959 DOI: 10.1016/S1040-8428(99)00053-0  0.054
2017 Yazdi HS, O'Sullivan TD, Leproux A, Hill B, Durkin A, Telep S, Lam J, Yazdi SS, Police AM, Carroll RM, Combs FJ, Strömberg T, Yodh AG, Tromberg BJ. Mapping breast cancer blood flow index, composition, and metabolism in a human subject using combined diffuse optical spectroscopic imaging and diffuse correlation spectroscopy. Journal of Biomedical Optics. 22: 45003. PMID 28384703 DOI: 10.1117/1.Jbo.22.4.045003  0.054
2004 Janardhan A, Swigut T, Hill B, Myers MP, Skowronski J. HIV-1 Nef binds the DOCK2-ELMO1 complex to activate rac and inhibit lymphocyte chemotaxis. Plos Biology. 2: E6. PMID 14737186 DOI: 10.1371/Journal.Pbio.0020006  0.054
2017 Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, ... ... Hill BT, et al. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era. Hematology (Amsterdam, Netherlands). 1-7. PMID 28105889 DOI: 10.1080/10245332.2017.1279842  0.054
2000 Hill BT, Moran E, Etiévant C, Perrin D, Masterson A, Larkin A, Whelan RD. Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1. Anti-Cancer Drugs. 11: 193-200. PMID 10831278 DOI: 10.1097/00001813-200003000-00007  0.054
1998 Etievant C, Barret JM, Kruczynski A, Perrin D, Hill BT. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Investigational New Drugs. 16: 3-17. PMID 9740539 DOI: 10.1023/A:1006022811895  0.054
2018 Ayers EC, Li S, Medeiros J, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, ... ... Hill BT, et al. Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy Blood. 132: 453-453. DOI: 10.1182/BLOOD-2018-99-115527  0.054
2018 Neelapu SS, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff PJ, Flinn IW, Farooq U, et al. 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Blood. 132: 2967-2967. DOI: 10.1182/BLOOD-2018-99-111368  0.054
2013 Skarbnik APZ, Portell CA, Maciejewski JP, Tiu RV, Pohlman B, Afable MG, Advani AS, Dean RM, Hill BT, Horwitz LJ, Jagadeesh D, Lichtin AE, Samaras C, Sekeres MA, Millenson M, et al. Association Of Large Granular Lymphocytic Leukemia (LGL) With B-Cell Lymphoproliferative Disorders Blood. 122: 1387-1387. DOI: 10.1182/blood.V122.21.1387.1387  0.054
1993 Whelan RDH, Hill BT. Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation Breast Cancer Research and Treatment. 26: 23-39. PMID 8400321 DOI: 10.1007/BF00682697  0.053
1987 Hill BT, Whelan RD, Gibby EM, Sheer D, Hosking LK, Shellard SA, Rupniak HT. Establishment and characterisation of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies. International Journal of Cancer. Journal International Du Cancer. 39: 219-25. PMID 3804493 DOI: 10.1002/ijc.2910390216  0.053
2015 Lau JE, Weber C, Earl M, Rybicki LA, Carlstrom KD, Wenzell CM, Hill BT, Majhail NS, Kalaycio M. Outcomes after autologous SCT in lymphoma patients grouped by weight. Bone Marrow Transplantation. 50: 652-7. PMID 25665041 DOI: 10.1038/bmt.2014.327  0.053
2019 Hu R, Wei W, Gonter-Aubin K, Pinilla Ibarz J, Kabel CC, Mato AR, Madanat YF, Khajavian S, Shadman M, Hanlon A, Brander DM, Park JH, Tallman MS, Hill BT. Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis Blood. 134: 4004-4004. DOI: 10.1182/blood-2019-126381  0.053
2001 Kavallaris M, Verrills NM, Hill BT. Anticancer therapy with novel tubulin-interacting drugs. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 4: 392-401. PMID 12030786 DOI: 10.1054/drup.2002.0230  0.053
2020 Awada H, Mahfouz RZ, Durrani J, Kishtagari A, Jagadeesh D, Lichtin AE, Hill BT, Hamilton BK, Carraway HE, Nazha A, Majhail NS, Sobecks R, Visconte V, Kalaycio M, Sekeres MA, et al. Large granular lymphocytic laeukemia after solid organ and haematopoietic stem cell transplantation. British Journal of Haematology. PMID 31958160 DOI: 10.1111/bjh.16336  0.053
2015 Starr A, Fu P, Caimi PF, Campagnaro EL, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Meyerson H, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Outcomes and prognostic factors in marginal zone lymphoma: Case comprehensive cancer center cumulative experience of 358 cases. Journal of Clinical Oncology. 33: 8554-8554. DOI: 10.1200/Jco.2015.33.15_Suppl.8554  0.053
2018 Shanmugasundaram K, Goyal S, Switchenko JM, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, ... ... Hill BT, et al. Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL) Blood. 132: 4153-4153. DOI: 10.1182/Blood-2018-99-117547  0.053
1987 Bedford P, Shellard SA, Walker MC, Whelan RD, Masters JR, Hill BT. Differential expression of collateral sensitivity or resistance to cisplatin in human bladder carcinoma cell lines pre-exposed in vitro to either X-irradiation or cisplatin. International Journal of Cancer. Journal International Du Cancer. 40: 681-6. PMID 3679594  0.053
1990 Hill BT, Deuchars K, Hosking LK, Ling V, Whelan RD. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. Journal of the National Cancer Institute. 82: 607-12. PMID 1968980 DOI: 10.1093/Jnci/82.7.607  0.052
2019 Wang ML, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Peng W, et al. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study Blood. 134: 754-754. DOI: 10.1182/BLOOD-2019-126064  0.052
2020 Spiegel JY, Dahiya S, Jain MD, Tamaresis JS, Nastoupil L, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis LJ, Reagan P, Oluwole OO, McGuirk JP, Deol A, Goy A, ... ... Hill B, et al. Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. Blood. PMID 33156925 DOI: 10.1182/blood.2020006245  0.052
2019 Epperla N, Switchenko JM, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov A, Grover NS, Mathews S, Burkart M, ... ... Hill BT, et al. Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Blood. 134: 3997-3997. DOI: 10.1182/Blood-2019-128632  0.052
2020 Hamilton BK, Rybicki L, Strzalka C, Dabney J, Colver A, Lawrence C, Anwer F, Dean RM, Gerds AT, Hill BT, Jagadeesh D, Kalaycio ME, Pohlman B, Sobecks RM, Majhail NS. Measuring Patient-Reported Outcomes (PROs) in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients Biology of Blood and Marrow Transplantation. 26: S67-S68. DOI: 10.1016/j.bbmt.2019.12.236  0.052
2019 Ruchlemer R, Ben-Ami R, Bar-Meir M, Brown JR, Malphettes M, Mous R, Tonino SH, Soussain C, Barzic N, Messina JA, Jain P, Cohen R, Hill B, Mulligan SP, Nijland M, et al. Ibrutinib associated invasive fungal diseases in patients with CLL and non-Hodgkin lymphoma: an observational study. Mycoses. PMID 31520441 DOI: 10.1111/Myc.13001  0.052
2022 Mian A, Bhattarai N, Sheu M, Ondrejka SL, Caimi PF, Hill BT. Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies. British Journal of Haematology. PMID 35733291 DOI: 10.1111/bjh.18333  0.052
1994 Hill BT, Whelan RD, Hurst HC, McClean S. Identification of a distinctive P-glycoprotein-mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated X-irradiation. Cancer. 73: 2990-9. PMID 7911070 DOI: 10.1002/1097-0142(19940615)73:12<2990::AID-CNCR2820731217>3.0.CO;2-L  0.052
1994 Hosking LK, Whelan RD, Shellard SA, Davies SL, Hickson ID, Danks MK, Hill BT. Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide. International Journal of Cancer. Journal International Du Cancer. 57: 259-67. PMID 7908897  0.052
1999 van Hille B, Clerc X, Creighton AM, Hill BT. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds. British Journal of Cancer. 81: 800-7. PMID 10555749 DOI: 10.1038/sj.bjc.6690767  0.052
2000 Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ. Cisplatin resistance and oncogenes--a review. Anti-Cancer Drugs. 11: 225-36. PMID 10898536 DOI: 10.1097/00001813-200004000-00001  0.051
1993 Lawton PA, Spittle MF, Ostrowski MJ, Young T, Madden F, Folkes A, Hill BT, MacRae K. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma Clinical Oncology. 5: 80-84. PMID 8481365 DOI: 10.1016/S0936-6555(05)80851-9  0.051
2019 Khouri J, Rybicki L, Majhail NS, Kalaycio M, Pohlman B, Hill B, Jagadeesh D, Dean R, Hamilton B, Sobecks R, Koo A, Liu H. Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation. Journal of Clinical Apheresis. PMID 31381194 DOI: 10.1002/jca.21739  0.051
1991 Dempke WCM, Shellard SA, Fichtinger-Schepman AMJ, Hill BT. Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro Carcinogenesis. 12: 525-528. PMID 1901253  0.051
2022 Gaffney KJ, Urban TA, Lucena M, Anwer F, Dean RM, Gerds AT, Hamilton BK, Jagadeesh D, Kalaycio ME, Khouri J, Pohlman B, Sobecks R, Winter A, Rybicki L, Majhail NS, ... Hill BT, et al. Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 10781552221104422. PMID 35673764 DOI: 10.1177/10781552221104422  0.051
2020 Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death & Disease. 11: 941. PMID 33139702 DOI: 10.1038/s41419-020-03144-y  0.051
1993 McClean S, Hosking LK, Hill BT. Dominant expression of multiple drug resistance after in vitro x- irradiation exposure in intraspecific Chinese hamster ovary hybrid cells Journal of the National Cancer Institute. 85: 48-53. PMID 8093217  0.051
2000 Perrin D, Hill BT. Tomorrow's anticancer agents: inhibitors of Ras farnesylation. Exs. 89: 153-79. PMID 10997288  0.051
2015 Madanat Y, Rybicki LA, Jagadeesh D, Dean RM, Pohlman BL, Kalaycio ME, Smith MR, Hill BT. Long term outcomes of hairy cell leukemia patients treated with first and subsequent line with purine analog: The Cleveland Clinic experience. Journal of Clinical Oncology. 33: e18034-e18034. DOI: 10.1200/jco.2015.33.15_suppl.e18034  0.051
1999 Barret JM, Etiévant C, Fahy J, Lhomme J, Hill BT. Novel artificial endonucleases inhibit base excision repair and potentiate the cytotoxicity of DNA-damaging agents on L1210 cells. Anti-Cancer Drugs. 10: 55-65. PMID 10194548  0.051
1994 Taverna P, Hansson J, Scanlon KJ, Hill BT. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis. 15: 2053-6. PMID 7923602  0.051
2019 Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, et al. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 12-20. PMID 30659125 DOI: 10.6004/Jnccn.2019.0002  0.051
2014 Collie AM, Hill BT, Stevens GH, Fenner K, Gazdick E, Hsi ED. Flow cytometric analysis of cerebrospinal fluid has low diagnostic yield in samples without atypical morphology or prior history of hematologic malignancy. American Journal of Clinical Pathology. 141: 515-21. PMID 24619752 DOI: 10.1309/AJCP8IB8FRQDVPXL  0.051
2019 Bond D, Switchenko J, Maddocks K, Churnetski M, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson J, Barta S, Hill B, Salwaha Y, Martin P, Maldonado E, et al. OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCING FRONTLINE TREATMENT FAILURE: A MULTICENTER RETROSPECTIVE STUDY Hematological Oncology. 37: 408-410. DOI: 10.1002/Hon.77_2631  0.05
1988 Hill BT, Whelan RDH, Hosking LK. Use of human neuroblastoma continuous cell lines for in vitro drug sensitivity screening Investigational New Drugs. 6: 11-18. PMID 3410662 DOI: 10.1007/BF00170774  0.05
2018 Winter AM, Nastoupil LJ, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, ... ... Hill BT, et al. Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival Blood. 132: 4146-4146. DOI: 10.1182/BLOOD-2018-99-118530  0.05
2016 Jagadeesh D, Rybicki L, Abounader D, Dean RM, Hill B, Liu H, Sobecks RM, Hamilton BK, Gerds A, Ferraro C, Starn J, Winslow V, Pohlman B, Kalaycio ME, Bolwell B, et al. Durable Long-Term Remission with Allogeneic Hematopoietic Cell Transplantation (HCT) for Relapsed/Refractory Follicular Lymphoma (FL) Biology of Blood and Marrow Transplantation. 22: S223-S224. DOI: 10.1016/j.bbmt.2015.11.627  0.05
2016 Dhir A, Hanna R, Rybicki L, Abounader D, Flagg A, Hamilton BK, Hill B, Jagadeesh D, Liu H, Gerds A, Kalaycio ME, Bolwell B, Majhail NS. Incidence and Risk Factors for Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia Biology of Blood and Marrow Transplantation. 22: S201-S202. DOI: 10.1016/j.bbmt.2015.11.592  0.05
2016 Nguyen VT, Pophali PA, Tsai JP, Jagadeesh D, Dean RM, Pohlman B, Morgan DS, Greer JP, Smith MR, Hill BT, Reddy NM. Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planning. British Journal of Haematology. PMID 27409578 DOI: 10.1111/bjh.14236  0.05
2017 Bates D, Bolwell B, Majhail NS, Rybicki L, Yurch M, Abounader D, Kohuth J, Jarancik S, Koniarczyk H, McLellan L, Dabney J, Lawrence C, Gallagher L, Kalaycio M, Sobecks R, ... ... Hill B, et al. Music Therapy for Symptom Management after Autologous Stem Cell Transplantation: Results from a Randomized Study. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28533058 DOI: 10.1016/j.bbmt.2017.05.015  0.05
1996 Hill BT. Drug resistance: An overview of the current state of the art International Journal of Oncology. 9: 197-203.  0.05
1994 Hill BT, Hosking LK. Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance. Cancer Chemotherapy and Pharmacology. 33: 317-24. PMID 8281626 DOI: 10.1007/BF00685907  0.05
2019 Matasar MJ, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT, Phillips TJ, Jerkeman M, Magagnoli M, Nastoupil LJ, Persky DO, Okosun J. Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. The Oncologist. PMID 31346132 DOI: 10.1634/theoncologist.2019-0138  0.05
1994 Hill BT, Whelan RDH, Shellard SA, McClean S, Hosking LK. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro Investigational New Drugs. 12: 169-182. PMID 7896535 DOI: 10.1007/BF00873957  0.05
2017 Khouri J, Rybicki L, Majhail N, Kalaycio M, Copelan E, Pohlman B, Hill B, Dean R, Lazaryan A, Hamilton B, Andresen S, Sobecks R, Bolwell B, Liu H. Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days. Journal of Clinical Apheresis. PMID 29134688 DOI: 10.1002/jca.21605  0.05
2018 Koffman B, Dennison B, Kennard K, Byrd JC, Pagel JM, Davids MS, Nabhan C, Kay NE, Siddiqi T, Brander DM, Stephens DM, Hill BT, Pinilla-Ibarz J, Cheson BD, Rosen ST, et al. A U.S.-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts). Journal of Clinical Oncology. 36: 7532-7532. DOI: 10.1200/Jco.2018.36.15_Suppl.7532  0.049
1992 Whelan RDH, Waring CJ, Wolf CR, Hayes JD, Hosking LK, Hill BT. Over-expression of P-glycoprotein and glutathione S-transferase PI in mice MCF-7 cells selected for vincristine resistance in vitro International Journal of Cancer. 52: 241-246. PMID 1355756 DOI: 10.1002/ijc.2910520215  0.049
2017 Waldron M, Winter A, Hill BT. Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax. Clinical Pharmacokinetics. PMID 28343293 DOI: 10.1007/s40262-017-0529-1  0.049
2019 Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, et al. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. British Journal of Haematology. PMID 31682002 DOI: 10.1111/bjh.16271  0.049
2017 Narkhede M, Rybicki L, Abounader Ccrp D, Bolwell B, Dean R, Gerds AT, Hanna R, Hill B, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS, Hamilton BK. The Association of Histologic Grade with Acute Graft-versus-Host Disease Response and Outcomes. American Journal of Hematology. PMID 28376566 DOI: 10.1002/ajh.24749  0.049
1993 Hill BT, Van Der Graaf WTA, Hosking LK, De Vries EGE, Mulder NH, Whelan RDH. Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro International Journal of Cancer. 55: 330-337. PMID 8103761  0.049
1998 Daley L, Guminski Y, Demerseman P, Kruczynski A, Etiévant C, Imbert T, Hill BT, Monneret C. Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide, and NK 611. Journal of Medicinal Chemistry. 41: 4475-85. PMID 9804687 DOI: 10.1021/Jm9800752  0.048
1999 Jean-Decoster C, Brichese L, Barret JM, Tollon Y, Kruczynski A, Hill BT, Wright M. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anti-Cancer Drugs. 10: 537-43. PMID 10885901  0.048
2014 Rosko AE, McColl KS, Zhong F, Ryder CB, Chang MJ, Sattar A, Caimi PF, Hill BT, Al-Harbi S, Almasan A, Distelhorst CW. Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment. Journal of Leukemia (Los Angeles, Calif.). 2. PMID 25984552 DOI: 10.4172/2329-6917.1000160  0.048
1989 Maynard KR, Hosking LK, Hill BT. Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA. Chemico-Biological Interactions. 71: 353-65. PMID 2582540 DOI: 10.1016/0009-2797(89)90110-5  0.048
2015 Hill BT, Tubbs RR, Smith MR. Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin. Leukemia & Lymphoma. 56: 1552-3. PMID 24717110 DOI: 10.3109/10428194.2014.911865  0.048
2013 Collie AMB, Hill BT, Manilich EA, Smith MR, Hsi ED. CD30 Immunohistochemical Expression In Diffuse Large B-Cell Lymphoma Is Associated With Decreased Overall Survival and The Non-Germinal Center Molecular Subtype Blood. 122: 4318-4318. DOI: 10.1182/blood.V122.21.4318.4318  0.048
2015 Hamilton BK, Rybicki L, Abounader D, Andresen S, Kalaycio M, Sobecks R, Pohlman B, Hanna R, Dean R, Duong H, Hill B, Bolwell B, Copelan E. Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer. Hematology/Oncology and Stem Cell Therapy. PMID 26183670 DOI: 10.1016/j.hemonc.2015.06.005  0.047
1989 Hill BT, Hosking LK, Shellard SA, Whelan RDH. Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro Cancer Chemotherapy and Pharmacology. 23: 140-144. PMID 2924371 DOI: 10.1007/BF00267944  0.047
1999 van Hille B, Perrin D, Hill BT. Differential in vitro interactions of a series of clinically useful topoisomerase-interacting compounds with the cleavage/religation activity of the human topoisomerase IIalpha and IIbeta isoforms. Anti-Cancer Drugs. 10: 551-60. PMID 10885903  0.047
2002 Kruczynski A, Hill BT. Classic in vivo cancer models: three examples of mouse models used in experimental therapeutics. Current Protocols in Pharmacology / Editorial Board, S.J. Enna (Editor-in-Chief) ... [Et Al.]. Unit5.24. PMID 21959766 DOI: 10.1002/0471141755.ph0524s15  0.047
2018 El-Asmar J, Rybicki L, Bernhard L, Coffman J, Corrigan D, Dean RM, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio ME, Liu H, Pohlman B, Serafino S, Urban TA, et al. Complication Rates and Resource Utilization in the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation (Allo HCT) Using Related Haploidentical Donors (Haplo) or Umbilical Cord Blood (UCB) Biology of Blood and Marrow Transplantation. 24: S285-S286. DOI: 10.1016/j.bbmt.2017.12.256  0.047
1987 Gibby EM, Boyse O, Hill BT. Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and-resistant murine and human tumour cell lines in vitro Cancer Chemotherapy and Pharmacology. 20: 5-7. PMID 3621454 DOI: 10.1007/BF00252950  0.047
2015 Hamilton BK, Law AD, Rybicki L, Abounader D, Dabney J, Dean R, Duong HK, Gerds AT, Hanna R, Hill BT, Jagadeesh D, Kalaycio ME, Lawrence C, McLellan L, Pohlman B, et al. Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients. Bone Marrow Transplantation. PMID 26030045 DOI: 10.1038/bmt.2015.122  0.047
2001 Fahy J, Hill BT. Tubulin-interacting agents. Epilogue. Current Pharmaceutical Design. 7: 1297-301. PMID 11472269 DOI: 10.2174/1381612013397447  0.047
2019 Cohen JB, Switchenko JM, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov A, Grover NS, Mathews S, Burkart M, ... ... Hill BT, et al. Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Blood. 134: 3483-3483. DOI: 10.1182/Blood-2019-128864  0.047
2018 Roeker LE, Fox CP, Eyre TA, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Lamanna N, Cheson B, Singavi AK, Coombs CC, Barr P, et al. Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings Blood. 132: 4410-4410. DOI: 10.1182/blood-2018-99-118159  0.047
2017 Ali MM, Rybicki L, Nomani L, Rouphail B, Dean RM, Hill BT, Jagadeesh D, Pohlman B, Hsi ED, Smith MR. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. Clinical Lymphoma, Myeloma & Leukemia. PMID 28789937 DOI: 10.1016/j.clml.2017.07.002  0.047
1988 Bedford P, Fichtinger-Schepman AM, Shellard SA, Walker MC, Masters JR, Hill BT. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Research. 48: 3019-24. PMID 3365691  0.047
2019 Bennani NN, Maurer MJ, Nastoupil LJ, Jain MD, Chavez JC, Cashen AF, Dahiya S, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Sehgal AR, Goy A, Hill BT, et al. Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium Blood. 134: 763-763. DOI: 10.1182/blood-2019-129097  0.047
2018 Flagg A, Money L, Bielek K, Majhail NS, Kalaycio ME, Dean RM, Gerds AT, Hill BT, Liu H, Hamilton BK, Jagadeesh D, Sobecks RM, Hanna R. Resolution of Secondary Thrombocytopenia with Thrombopoietin Receptor Agonists in Two Allogeneic Hematopoietic Cell Transplant Recipients Treated at a Pediatric Center Biology of Blood and Marrow Transplantation. 24: S445. DOI: 10.1016/j.bbmt.2017.12.542  0.046
1987 Bedford P, Walker MC, Sharma HL, Perera A, McAuliffe CA, Masters JR, Hill BT. Factors influencing the sensitivity of two human bladder carcinoma cell lines to cis-diamminedichloroplatinum(II). Chemico-Biological Interactions. 61: 1-15. PMID 3815585 DOI: 10.1016/0009-2797(87)90015-9  0.046
2013 Hamilton BK, Bolwell B, Kalaycio M, Rybicki L, Hanna R, Sobecks R, Pohlman B, Andresen S, Dean R, Duong H, Hill B, Copelan E. Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hematopoietic cell transplantation. Bone Marrow Transplantation. 48: 1578-80. PMID 23749105 DOI: 10.1038/bmt.2013.89  0.046
1991 Whelan RDH, Hosking LK, Hill BT. A lack of Adriamycin (ADR) resistance in Chinese hamster ovary (CHO) cells overexpressing P-glycoprotein (Pgp) following in vitro exposure to fractionated X-irradiation Biochemical Society Transactions. 19: 125S. PMID 1679723  0.046
2022 Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, McGuirk J, Deol A, Sehgal A, Goy A, ... Hill BT, et al. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clinical Lymphoma, Myeloma & Leukemia. PMID 35780055 DOI: 10.1016/j.clml.2022.05.004  0.046
1993 McClean S, Hosking LK, Hill BT. Expression of p-glycoprotein-mediated drug resistance in CHO cells surviving a single x-ray dose of 30 gy International Journal of Radiation Biology. 63: 765-773. PMID 8100264 DOI: 10.1080/09553009314552171  0.046
2019 Patel SS, Rybicki LA, Yurch M, Thomas D, Liu H, Dean R, Jagadeesh D, Hill B, Pohlman B, Bolwell B, Hanna R, Hamilton BK, Kalaycio M, Gerds AT, Cober E, et al. Influence of major histocompatibility complex class I chain-related gene a polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. Hematology/Oncology and Stem Cell Therapy. PMID 31881183 DOI: 10.1016/j.hemonc.2019.10.001  0.046
2019 Lucena M, Urban TA, Huang I, Gaffney K, Zembillas A, Dean RM, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio ME, Pohlman B, Sobecks RM, Rybicki L, Majhail NS. Evaluation of Corticosteroids for Engraftment Syndrome (ES) Prophylaxis in Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT) with High-Dose Melphalan (MEL) Biology of Blood and Marrow Transplantation. 25: S281. DOI: 10.1016/j.bbmt.2018.12.350  0.046
2019 Bond DA, Switchenko JM, Maddocks KJ, Churnetski MC, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Sawalha Y, Hill BT, Martin P, Gordon MJ, et al. Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma Blood. 134: 753-753. DOI: 10.1182/Blood-2019-128415  0.046
2020 Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato A, Winter A, Hill B, Gaballa S, Danilov A, Phillips T, et al. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica. PMID 33054118 DOI: 10.3324/haematol.2020.256388  0.045
2001 Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. British Journal of Cancer. 84: 290-5. PMID 11161390 DOI: 10.1054/bjoc.2000.1587  0.045
2018 Mato AR, Sarraf Yazdy M, Hill BT, Shadman M, Tuncer H, Winter AM, Kennard K, Allan JN, Ujjani CS, Brander DM, Nabhan C, Barr P, Brown JR, Fox CP, Rhodes J, et al. Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study Blood. 132: 4759-4759. DOI: 10.1182/blood-2018-99-119015  0.045
2019 Hill BT, Switchenko JM, Martin P, Churnetski MC, Sawalha Y, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov A, Grover NS, et al. Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant Blood. 134: 1525-1525. DOI: 10.1182/Blood-2019-129404  0.045
2004 Hill B, Kyprianou N. Effect of permixon on human prostate cell growth: lack of apoptotic action. The Prostate. 61: 73-80. PMID 15287095 DOI: 10.1002/Pros.20088  0.045
2010 Hill B, Agha M, Kalaycio M. Successful Allogeneic Stem Cell Transplantation Of Patients With CML And Monosomy 7 Biology of Blood and Marrow Transplantation. 16: S297. DOI: 10.1016/j.bbmt.2009.12.422  0.044
2017 Platt S, Al Zahrani Y, Singh N, Hill B, Cherian S, Singh AD. Extranodal Marginal Zone Lymphoma of Ocular Adnexa: Outcomes following Radiation Therapy. Ocular Oncology and Pathology. 3: 181-187. PMID 29134184 DOI: 10.1159/000453615  0.044
2001 Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Molecular Pharmacology. 60: 225-32. PMID 11408618 DOI: 10.1124/Mol.60.1.225  0.044
2006 Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, Giavazzi R, Hill BT, Taraboletti G. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. European Journal of Cancer (Oxford, England : 1990). 42: 2821-32. PMID 16973349 DOI: 10.1016/j.ejca.2006.06.019  0.044
1994 McClean S, Hill BT. Modified multiple drug resistance phenotype of Chinese hamster ovary cells selected with X-rays and vincristine versus X-rays only. British Journal of Cancer. 69: 711-6. PMID 7908216  0.043
2015 Askar M, Majhail NS, Rybicki L, Zhang A, Thomas D, Chen D, Abounader D, Bolwell B, Dean RM, Duong HK, Gerds A, Hamilton B, Hanna R, Hill B, Jagadeesh D, et al. Single Nucleotide Gene Polymorphisms (SNP) in the Gamma Block of the Major Histocompatibility Complex (MHC) Are Independent Risk Factors for Severe Acute Graft Versus Host Disease (GVHD) in Unrelated Donor Hematopoietic Cell Transplantation (HCT) Biology of Blood and Marrow Transplantation. 21: S326-S327. DOI: 10.1016/j.bbmt.2014.11.519  0.043
2019 Hu R, Winter A, Hill BT. The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma. Current Oncology Reports. 21: 44. PMID 30941515 DOI: 10.1007/s11912-019-0792-4  0.043
2015 Hamilton BK, Mani S, Rybicki L, Abounader D, Andresen S, Bolwell B, Dean RM, Duong HK, Gerds A, Hanna R, Hill B, Jagadeesh D, Kalaycio ME, Pohlman B, Sobecks R, et al. Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Cellular Infusion for Relapse after Transplant Biology of Blood and Marrow Transplantation. 21: S330. DOI: 10.1016/j.bbmt.2014.11.526  0.043
2007 Rajniak P, Mancinelli C, Chern RT, Stepanek F, Farber L, Hill BT. Experimental study of wet granulation in fluidized bed: impact of the binder properties on the granule morphology. International Journal of Pharmaceutics. 334: 92-102. PMID 17207948 DOI: 10.1016/j.ijpharm.2006.10.040  0.042
2018 Koffman B, Dennison B, Kennard K, Byrd JC, Furman RR, Pagel JM, Davids MS, Nabhan C, Kay NE, Siddiqi T, Brander DM, Wierda WG, Stephens DM, Hill BT, Pinilla Ibarz J, et al. Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States Blood. 132: 4414-4414. DOI: 10.1182/blood-2018-99-112971  0.042
2010 Hill BT, Bolwell BJ, Rybicki L, Sekeres MA, Mansour M, Dean R, Pohlman B, Tench S, Sobecks R, Andresen S, Kalaycio M, Copelan EA. Cigarette Smoking Is Associated with Increased Rates of Fungal Infection and Increased Mortality After Allogeneic Transplantation Blood. 116: 2321-2321. DOI: 10.1182/blood.V116.21.2321.2321  0.042
2017 Winter AM, Landsburg DJ, Mato AR, Isaac K, Hernandez-Ilizaliturri FJ, Reddy N, Smith S, Shadman M, Smith MR, Caimi P, Jagadeesh D, Hill BT. A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. Blood. PMID 28794071 DOI: 10.1182/blood-2017-05-786988  0.042
2018 Miller GD, Moore C, Nair V, Hill B, Willick SE, Rogol AD, Eichner D. HPT-Axis Effects and Urinary Detection Following Clomiphene Administration in Males. The Journal of Clinical Endocrinology and Metabolism. PMID 30295816 DOI: 10.1210/jc.2018-01159  0.042
2019 Jacobs MT, Jain MD, Spiegel JY, Nastoupil LJ, Li Y, Feng G, Lunning MA, Lekakis LJ, Dahiya S, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Sehgal AR, Goy A, ... Hill BT, et al. Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium Blood. 134: 1583-1583. DOI: 10.1182/blood-2019-131168  0.041
2017 Leproux, O'Sullivan TD, Cerussi A, Durkin A, Hill B, Hylton N, Yodh AG, Carp SA, Boas D, Jiang S, Paulsen KD, Pogue B, Roblyer D, Yang W, Tromberg BJ. Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial Journal of Biomedical Optics. 22: 121604. PMID 29389104 DOI: 10.1117/1.Jbo.22.12.121604  0.041
2019 Khouri J, Reu F, Majhail NS, Gerds A, Jagadeesh D, Dean R, Sobecks R, Hamilton BK, Pohlman B, Hill BT, Corrigan D, Kalaycio M, Bolwell BJ, Liu HD. Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia. PMID 31053548 DOI: 10.1016/j.clml.2019.03.019  0.041
1991 Dempke WCM, Hosking LK, Shellard SA, Hill BT. Differential cisplatin responses in human carcinoma cell lines pre-exposed to fractionated X-irradiation Biochemical Society Transactions. 19: 121S. PMID 1889526  0.041
2018 Thompson M, Nabhan C, Cheson BD, Allan JN, Barr PM, Skarbnik AP, Jacobs R, Ujjani CS, Furman RR, Schuster SJ, Shah NN, Pagel JM, Hill BT, Brander DM, Shadman M, et al. Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies. Journal of Clinical Oncology. 36: 6577-6577. DOI: 10.1200/jco.2018.36.15_suppl.6577  0.041
2013 Bodo J, Zhao X, Sharma A, Hill BT, Portell CA, Lannutti BJ, Almasan A, Hsi ED. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. British Journal of Haematology. 163: 72-80. PMID 23889282 DOI: 10.1111/Bjh.12498  0.041
1989 Whelan RD, Hosking LK, Townsend AJ, Cowan KH, Hill BT. Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines Cancer Communications. 1: 359-365. PMID 2702041 DOI: 10.3727/095535489820875057  0.041
2018 Patel SS, Rybicki L, Yurch M, Thomas D, Jagadeesh D, Dean RM, Liu H, Flagg A, Gerds AT, Hill BT, Hanna R, Hamilton BK, Pohlman B, Kalaycio ME, Bolwell B, et al. Impact of MHC Class I Chain-Related Gene a (MICA) Mismatch on Haploidentical Hematopoietic Cell Transplantation Outcomes Biology of Blood and Marrow Transplantation. 24: S418-S419. DOI: 10.1016/j.bbmt.2017.12.428  0.04
2003 Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Molecular Cancer Therapeutics. 2: 427-36. PMID 12748304  0.04
2002 Hill B, Kyprianou N. Sequencing hormonal ablation and radiotherapy in prostate cancer: a molecular and therapeutic prespective (Review). Oncology Reports. 9: 1151-6. PMID 12375010 DOI: 10.3892/Or.9.6.1151  0.04
2018 Stephens DM, Boucher K, Kander E, Parikh SA, Parry E, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato AR, Winter AM, Hill BT, Gaballa S, Danilov AV, Phillips TJ, et al. Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration Blood. 132: 1648-1648. DOI: 10.1182/BLOOD-2018-99-113173  0.04
2012 Hill BT, Weil AC, Kalaycio M, Cook JR. Pulmonary involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma is a specific pathologic finding independent of inflammatory infiltration. Leukemia & Lymphoma. 53: 589-95. PMID 21929283 DOI: 10.3109/10428194.2011.623252  0.04
2018 Patel SS, Rybicki L, Corrigan D, Jagadeesh D, Dean RM, Liu H, Flagg A, Gerds AT, Hill BT, Hanna R, Bolwell B, Pohlman B, Kalaycio ME, Sobecks RM, Majhail NS, et al. Propensity Matched Analysis of Autologous Hematopoietic Stem Cell Transplantation Outcomes in Solid Organ Transplant Recipients Biology of Blood and Marrow Transplantation. 24: S285. DOI: 10.1016/j.bbmt.2017.12.255  0.04
2019 Hill BT, Roberts ZJ, Xue A, Rossi JM, Smith MR. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation. PMID 31471571 DOI: 10.1038/s41409-019-0657-3  0.04
2019 Mato AR, Roeker LE, Eyre TA, Jacobs R, Hill BT, Lamanna N, Brander DM, Shadman M, Ujjani C, Yazdy M, Perini GF, Pinilla Ibarz J, Barrientos JC, Skarbnik A, Torka P, et al. Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies Blood. 134: 502-502. DOI: 10.1182/BLOOD-2019-123747  0.039
2014 Collie AM, Nölling J, Divakar KM, Lin JJ, Carver P, Durkin LM, Hill BT, Smith MR, Radivoyevitch T, Kong LI, Daly T, Murugesan G, Guenther-Johnson J, Dave SS, Manilich EA, et al. Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex® system. British Journal of Haematology. 167: 281-5. PMID 24961756 DOI: 10.1111/bjh.12983  0.039
2019 Romancik J, Switchenko JM, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov A, Grover NS, Mathews S, Burkhart M, ... ... Hill BT, et al. The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma Blood. 134: 5891-5891. DOI: 10.1182/Blood-2019-130249  0.039
2015 Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT, Kalaycio ME, Carraway HE, Mukherjee S, Sekeres MA, Maciejewski JP. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. Leukemia. PMID 26460209 DOI: 10.1038/Leu.2015.258  0.039
1988 Hill BT, Whelan RDH, Hosking LK, Shellard SA, Bedford P, Lock RB. Interactions between antitumor drugs and radiation in mammalian tumor cell lines: Differential drug responses and mechanisms of resistance following fractionated X-irradiation or continuous drug exposure in vitro Nci Monographs. 177-181. PMID 3352761  0.039
1998 Perrin D, van Hille B, Hill BT. Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents. Biochemical Pharmacology. 56: 503-7. PMID 9763227 DOI: 10.1016/S0006-2952(98)00082-3  0.038
2012 Cerussi AE, Warren R, Hill B, Roblyer D, Leproux A, Durkin AF, O'Sullivan TD, Keene S, Haghany H, Quang T, Mantulin WM, Tromberg BJ. Tissue phantoms in multicenter clinical trials for diffuse optical technologies. Biomedical Optics Express. 3: 966-71. PMID 22567589 DOI: 10.1364/Boe.3.000966  0.038
1991 Shellard SA, Fichtinger-Schepman AMJ, Hosking LK, Hill BT. Differential modulation of cisplatin cytotoxicity by human ovarian carcinoma cell lines in vitro Biochemical Society Transactions. 19: 126S. PMID 1889528  0.038
2019 Orellana-Noia VM, Isaac K, Wages NA, Malecek M, Bartlett NL, Voorhees TJ, Grover NS, Hwang SR, Bennani NN, Hu R, Hill BT, Mou E, Advani RH, Carter J, David KA, et al. Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis Blood. 134: 4027-4027. DOI: 10.1182/blood-2019-123572  0.038
2021 Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, et al. The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34168050 DOI: 10.1158/1078-0432.CCR-20-3993  0.037
2012 Hamilton B, Serafino S, Kalaycio M, Andresen S, Pohlman B, Dean R, Hill B, Hanna R, Duong H, Sweetenham J, Copelan E, Bolwell B, Sobecks R. Repeat Readmissions After Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT) Biology of Blood and Marrow Transplantation. 18: S284. DOI: 10.1016/j.bbmt.2011.12.221  0.037
2013 Hamilton BK, Rybicki L, Bolwell B, Kalaycio ME, Sekeres M, Sobecks R, Hanna R, Dean RM, Duong H, Hill B, Copelan EA. Risk Factors for Prolonged Length of Hospitalization in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 19: S290-S291. DOI: 10.1016/j.bbmt.2012.11.418  0.037
1997 Barret JM, Salles B, Provot C, Hill BT. Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplate assay. Carcinogenesis. 18: 2441-5. PMID 9450493 DOI: 10.1093/carcin/18.12.2441  0.037
2020 Gaffney K, Urban TA, Lucena M, Anwer F, Dean RM, Gerds AT, Hamilton BK, Jagadeesh D, Kalaycio ME, Khouri J, Pohlman B, Sobecks RM, Winter A, Rybicki L, Majhail NS, ... Hill BT, et al. Toxicity Analysis of Busulfan Pharmacokinetic Guided Therapeutic Dose Monitoring for Myeloablative Conditioning Regimens with Allogeneic Transplantation Biology of Blood and Marrow Transplantation. 26: S388-S389. DOI: 10.1016/j.bbmt.2019.12.313  0.036
2020 Gordon MJ, Sitlinger A, Salous T, Alqahtani H, Churnetski M, Rivera X, Wisniewski P, Cohen J, Patel K, Shadman M, Choi M, Hill B, Stephens D, Persky D, Brander D, et al. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. Leukemia Research. 106302. PMID 31982152 DOI: 10.1016/j.leukres.2020.106302  0.036
2017 Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, et al. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28171884 DOI: 10.1093/annonc/mdw???  0.036
2020 Eyre TA, Lamanna N, Roeker LE, Ujjani CS, Hill BT, Barr PM, Lansigan E, Cheson BD, Yazdy M, Allan JN, Rhodes J, Schuster SJ, Nabhan C, Skarbnik A, Leslie L, et al. Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica. PMID 32079693 DOI: 10.3324/haematol.2019.241539  0.036
2012 Hamilton B, Serafino S, Kalaycio M, Andresen S, Pohlman B, Dean R, Hill B, Hanna R, Duong H, Sweetenham J, Sweetenham J, Copelan E, Bolwell B, Sobecks R. Early Readmission Rates After Autologous and Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT) Biology of Blood and Marrow Transplantation. 18: S279. DOI: 10.1016/j.bbmt.2011.12.207  0.035
2018 Patel SS, Rybicki L, Yurch M, Thomas D, Jagadeesh D, Dean RM, Liu H, Flagg A, Cober E, Mossad SB, Gerds AT, Hill BT, Hanna R, Hamilton BK, Pohlman B, et al. Impact of MHC Class I Chain-Related Gene a (MICA) Mismatch on Umbilical Cord Blood Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 24: S190. DOI: 10.1016/j.bbmt.2017.12.300  0.035
2015 Choudhary GS, Tat TT, Misra S, Hill BT, Smith MR, Almasan A, Mazumder S. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics. Oncotarget. 6: 16912-25. PMID 26219338 DOI: 10.18632/Oncotarget.4857  0.035
2000 Workman RD, Lewis MJ, Hill BT. Enhancing the financial performance of a health system laboratory network using an information system. American Journal of Clinical Pathology. 114: 9-15. PMID 10884794 DOI: 10.1309/UQRF-AVN9-5V0Y-DTNK  0.035
2000 Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Research. 60: 5045-51. PMID 11016627  0.035
1996 Lamothe M, Perrin D, Blotières D, Leborgne M, Gras S, Bonnet D, Hill BT, Halazy S. Inhibition of farnesyl protein transferase by new farnesyl phosphonate derivatives of phenylalanine Bioorganic and Medicinal Chemistry Letters. 6: 1291-1296. DOI: 10.1016/0960-894X(96)00238-7  0.035
2019 Shadman M, Sail K, Manzoor BS, Yazdy MS, Hill BT, Tuncer HH, Allan JN, Ujjani CS, Emechebe N, Kamalakar R, Sharmokh S, Jiang DD, Pena G, Marshall T, Nielsen J, et al. Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study Blood. 134: 3048-3048. DOI: 10.1182/Blood-2019-131401  0.034
2015 Narkhede M, Rybicki L, Abounader D, Andresen S, Bolwell B, Dean RM, Duong HK, Gerds A, Hanna R, Hill B, Jagadeesh D, Kalaycio ME, Pohlman B, Sobecks R, Majhail NS, et al. The Impact of Histologic Grade on Acute Graft Versus Host Disease Response and Outcomes Biology of Blood and Marrow Transplantation. 21: S341. DOI: 10.1016/j.bbmt.2014.11.543  0.034
1990 Shellard S, Hosking L, Fichtinger-Schepman AM, Hill BT. Mechanisms of cisplatin cytotoxicity in human ovarian carcinoma cell lines Biochemical Society Transactions. 18: 622. PMID 2276474  0.034
1998 Hill BT, Beinlich B, Plachter H. Habitat preference of Lestes barbarus (FABRICIUS, 1798) (odonata, lestidae) on a low-intensity cattle pasture in the Sava floodplain (Croatia) Verhandlungen Der Gesellschaft Fur Okologie. 29: 539-545.  0.033
2017 Mehdi A, Rybicki L, Mossad S, Yurch M, Sekeres M, Gerds AT, Jagadeesh D, Hamilton B, Liu H, Dean R, Pohlman B, Sobecks R, Andresen S, Kalaycio M, Bolwell BJ, ... ... Hill BT, et al. Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection. Bone Marrow Transplantation. PMID 28869614 DOI: 10.1038/bmt.2017.184  0.033
2019 Roschewski M, Hill BT. One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 39: 467-476. PMID 31099693 DOI: 10.1200/EDBK_239065  0.033
2020 Lucena M, Urban TA, Gaffney K, Anwer F, Dean RM, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio ME, Pohlman B, Sobecks RM, Majhail NS. The Impact of Clinical Pharmacists in Hematopoietic Stem Cell Transplant (HSCT) Outpatient Clinic at an Academic Medical Center Biology of Blood and Marrow Transplantation. 26: S93. DOI: 10.1016/j.bbmt.2019.12.594  0.033
2019 Rhodes J, Sail K, Yazdy SM, Hill B, Shadman M, Tuncer H, Winter A, Kennard K, Allan J, Ujjani C, Brander D, Cho S, Sharmokh S, Jiang DD, Nabhan C, et al. FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT-NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY Hemasphere. 3: 142. DOI: 10.1097/01.HS9.0000559736.57279.87  0.033
1989 Shellard SA, Whelan RDH, Hill BT. Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumour cell lines in vitro British Journal of Cancer. 60: 288-290. PMID 2789933  0.033
1998 Allawi SJ, Hill BT, Shah NR. New frontiers for diagnostic testing: taking advantage of forces changing health care. Clinical Laboratory Management Review : Official Publication of the Clinical Laboratory Management Association / Clma. 12: 3-8. PMID 10178702  0.032
2019 Danilov AV, Pagel JM, Brown JR, Hill BT. Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia - Passé Yet? Hemasphere. 3: e275. PMID 31723845 DOI: 10.1097/HS9.0000000000000275  0.032
2017 Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, et al. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28130279 DOI: 10.1093/annonc/mdx031  0.032
2014 Hill BT. Etiology of cancer Clinical Ophthalmic Oncology: Basic Principles and Diagnostic Techniques, Second Edition. 13-19. DOI: 10.1007/978-3-642-40489-4_2  0.031
2019 Prieto D, Soto-Ferrari M, Tija R, Peña L, Burke L, Miller L, Berndt K, Hill B, Haghsenas J, Maltz E, White E, Atwood M, Norman E. Literature review of data-based models for identification of factors associated with racial disparities in breast cancer mortality. Health Systems (Basingstoke, England). 8: 75-98. PMID 31275571 DOI: 10.1080/20476965.2018.1440925  0.031
2020 Smith JM, Lathara M, Wright H, Hill B, Ganapati N, Srinivasa G, Denny CT. Advancing clinical cohort selection with genomics analysis on a distributed platform. Plos One. 15: e0231826. PMID 32324802 DOI: 10.1371/journal.pone.0231826  0.031
2019 Mato AR, Sail K, Yazdy MS, Hill BT, Shadman M, Manzoor BS, Tuncer HH, Allan JN, Ujjani CS, Sharmokh S, Jiang DD, Pena G, Marshall T, Nielsen J, Barr PM, et al. Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies Blood. 134: 1756-1756. DOI: 10.1182/Blood-2019-124600  0.031
1990 Eichten E, Hill B. An effective field theory for the calculation of matrix elements involving heavy quarks Physics Letters B. 234: 511-516. DOI: 10.1016/0370-2693(90)92049-O  0.03
2015 Al-Harbi S, Choudhary GS, Ebron JS, Hill BT, Vivekanathan N, Ting AH, Radivoyevitch T, Smith MR, Shukla GC, Almasan A. miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. Molecular Cancer. 14: 185. PMID 26537004 DOI: 10.1186/S12943-015-0460-8  0.03
1992 McClean S, Hill BT. An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugs in vitro Bba - Reviews On Cancer. 1114: 107-127. PMID 1360815 DOI: 10.1016/0304-419X(92)90010-V  0.03
2021 Khaksari K, Nguyen T, Hill B, Quang T, Perreault J, Gorti V, Malpani R, Blick E, González Cano T, Shadgan B, Gandjbakhche AH. Review of the efficacy of infrared thermography for screening infectious diseases with applications to COVID-19. Journal of Medical Imaging (Bellingham, Wash.). 8: 010901. PMID 33786335 DOI: 10.1117/1.JMI.8.S1.010901  0.03
2014 Sidana S, Jia X, Gerds AT, Hamilton BK, Tiu RV, Saunthararajah Y, Maciejewski JP, Reu FJ, Carraway H, Hill BT, Smith MR, Kalaycio ME, Suh JH, Sekeres MA, Mukherjee S. Risk of hematologic malignancies following radiation treatment for well-differentiated thyroid cancer in the United States over 37 years. Journal of Clinical Oncology. 32: 6633-6633. DOI: 10.1200/jco.2014.32.15_suppl.6633  0.03
2015 Fu S, Rybicki L, Abounader D, Andresen S, Bolwell B, Dean RM, Duong HK, Gerds A, Hamilton BK, Hanna R, Hill B, Jagadeesh D, Kalaycio ME, Pohlman B, Sobecks R, et al. Socioeconomic Status Influences Long-Term Outcomes in 1-Year Survivors after Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 21: S74. DOI: 10.1016/j.bbmt.2014.11.082  0.03
2019 Roeker LE, Fox CP, Eyre TA, Brander D, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Sarraf Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax treated CLL in routine clinical practice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31004001 DOI: 10.1158/1078-0432.CCR-19-0361  0.029
1991 McClean S, Whelan RDH, Hosking LK, Hill BT. Expression of drug resistance in Chinese hamster ovary (CHO) cells following X-ray pre-treatment in vitro Biochemical Society Transactions. 19: 278S. PMID 1685999  0.029
1987 Sheer D, Sheppard DM, Gorman PA, Ward B, Whelan RD, Hill BT. Cytogenetic analysis of four human ovarian carcinoma cell lines. Cancer Genetics and Cytogenetics. 26: 339-49. PMID 3471313 DOI: 10.1016/0165-4608(87)90068-9  0.029
1990 Hosking LK, Whelan RDH, Hill BT. Identification of a relationship between glutathione metabolism and drug sensitivities in a panel of human tumour cell lines Biochemical Society Transactions. 18: 621. PMID 2276473  0.029
2019 Hamilton BK, Serafino S, Rybicki L, Bernhard L, Elberson J, Hodgeman B, Starn J, Winslow V, Colver A, Dabney J, Lawrence C, Dean RM, Gerds AT, Hill BT, Jagadeesh D, et al. Day 100 Risk Assessment Tool Predicts 1-Year Mortality after Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 25: S137-S138. DOI: 10.1016/j.bbmt.2018.12.426  0.029
2022 Hegde PS, Rybicki L, Serafino S, Bernhard L, Corrigan D, Anwer F, Kalaycio M, Sobecks RM, Jagadeesh D, Hill BT, Dean RM, Khouri J, Winter AM, Pohlman B, Majhail NS, et al. Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant. Bone Marrow Transplantation. PMID 35428866 DOI: 10.1038/s41409-022-01677-8  0.028
2011 Mann RJ, Neaman KC, Hill B, Bajnrauh R, Martin MD. A novel technique for performing a tongue-lip adhesion-the tongue suspension technique. The Cleft Palate-Craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association. 49: 27-31. PMID 21413861 DOI: 10.1597/10-036  0.028
2020 Khare SM, Nguyen T, Anderson AA, Hill B, Romero R, Gandjbakhche AH. Evaluation of the human placenta optical scattering properties using continuous wave and frequency-domain diffuse reflectance spectroscopy. Journal of Biomedical Optics. 25. PMID 33155452 DOI: 10.1117/1.JBO.25.11.116001  0.028
2012 Lukenbill J, Mossad S, Butler R, Sobecks R, Andresen S, Copelan E, Dean R, Duong H, Kalaycio M, Hill B, Pohlman B, Sweetenham J, Bolwell B. Immunogenicity of Polysaccharide Pneumococcal Vaccination in Autologous Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 18: S237. DOI: 10.1016/j.bbmt.2011.12.099  0.028
2014 Hill BT, Caimi P, Kindwall-Keller T, Habecker B, Kalaycio M. Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL). British Journal of Haematology. 164: 297-9. PMID 24131326 DOI: 10.1111/bjh.12604  0.028
2021 Lam J, Hill B, Quang T, Amelard R, Kim S, Yazdi H, Warren R, Cutler K, Tromberg B. Multi-modal diffuse optical spectroscopy for high-speed monitoring and wide-area mapping of tissue optical properties and hemodynamics. Journal of Biomedical Optics. 26. PMID 34390234 DOI: 10.1117/1.JBO.26.8.085002  0.027
2018 Zhu Y, Toth AJ, Lowry AM, Blackstone EH, Hill BT, Mick SL. Cardiac Surgery Outcomes in Patients With Chronic Lymphocytic Leukemia. The Annals of Thoracic Surgery. PMID 29455840 DOI: 10.1016/j.athoracsur.2017.11.014  0.027
2021 Kapoor I, Bodo J, Hill BT, Almasan A. Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies. Cell Death & Disease. 12: 1061. PMID 34750354 DOI: 10.1038/s41419-021-04353-9  0.027
2016 Hill BT. It's Personal: Achieving Optimal Busulfan Exposure for all Patients. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27164063 DOI: 10.1016/j.bbmt.2016.04.024  0.027
1998 Barret JM, Hill BT. DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets. Anti-Cancer Drugs. 9: 105-23. PMID 9510496  0.026
2018 Hill B, Kambeyanda R, Fewell D, Bryant S, Delaney KO, Herrera FA. Single-Institution Experience With Component Separation for Ventral Hernia Repair: A Retrospective Review. Annals of Plastic Surgery. PMID 29481484 DOI: 10.1097/SAP.0000000000001349  0.026
2020 Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, Duggal A, Turtle CJ, Patel K, Lin Y, May HP, Gallo de Moraes A, Maus MV, Frigault MJ, Brudno JN, et al. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care. 58: 58-64. PMID 32361219 DOI: 10.1016/J.Jcrc.2020.04.008  0.025
1990 Sheer D, Gorman PA, Whelan R, Hill BT. Cytogenetic analysis of a cell line established from a Krukenberg tumor. Cancer Genetics and Cytogenetics. 46: 71-4. PMID 2331685 DOI: 10.1016/0165-4608(90)90010-8  0.024
2007 Walsh M, Young B, Hill B, Kittredge K, Horn T. The effect of ball-carrying technique and experience on sprinting in rugby union. Journal of Sports Sciences. 25: 185-92. PMID 17127593 DOI: 10.1080/02640410600630571  0.024
1998 van Hille B, Hill BT. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents. Cancer Chemotherapy and Pharmacology. 42: 345-56. PMID 9771947 DOI: 10.1007/s002800050828  0.023
2014 Orense RP, Hickman NA, Hill BT, Pender MJ. Spatial evaluation of liquefaction potential in Christchurch following the 2010/2011 Canterbury earthquakes International Journal of Geotechnical Engineering. 8: 420-425. DOI: 10.1179/1939787913Y.0000000028  0.023
2006 Hill BT, Workman R. Pro: benchmarking is the absolute prerequisite for timely and significant business process improvement. Clinical Leadership & Management Review : the Journal of Clma. 20: E2. PMID 17132457  0.023
2019 Mangul S, Mosqueiro T, Abdill RJ, Duong D, Mitchell K, Sarwal V, Hill B, Brito J, Littman RJ, Statz B, Lam AK, Dayama G, Grieneisen L, Martin LS, Flint J, et al. Challenges and recommendations to improve the installability and archival stability of omics computational tools. Plos Biology. 17: e3000333. PMID 31220077 DOI: 10.1371/Journal.Pbio.3000333  0.021
1991 Hill BT. Interactions between antitumour agents and radiation and the expression of resistance Cancer Treatment Reviews. 18: 149-190. PMID 1821327 DOI: 10.1016/0305-7372(91)90006-L  0.02
2019 Sano D, Lekakis L, Feng L, Nastoupil L, Jain M, Spiegel J, Dahiya S, Lin Y, Ghobadi A, Lunning M, Hill B, Reagan P, Oluwole O, McGuirk J, Sehgal A, et al. SAFETY AND EFFICACY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN OLDER PATIENTS: RESULTS FROM THE US LYMPHOMA CAR-T CONSORTIUM Hematological Oncology. 37: 304-305. DOI: 10.1002/HON.113_2630  0.02
1990 Berger MR, Hellmann K, Hill BT, Schmahl D, Zeller WJ. Improvement of antitumor drug therapeutic index by toxicity reduction: Foreword Cancer Treatment Reviews. 17: 107. DOI: 10.1016/0305-7372(90)90033-C  0.019
2019 Amelard R, Lam JH, Hill B, Durkin A, Cutler K, Tromberg BJ. Monocular 3D Probe Tracking for Generating Sub-Surface Optical Property Maps from Diffuse Optical Spectroscopic Imaging. Ieee Transactions On Bio-Medical Engineering. PMID 31670661 DOI: 10.1109/Tbme.2019.2950004  0.019
2017 O'Sullivan TD, No K, Matlock A, Warren RV, Hill B, Cerussi AE, Tromberg BJ. Vertical-cavity surface-emitting laser sources for gigahertz-bandwidth, multiwavelength frequency-domain photon migration. Journal of Biomedical Optics. 22: 1-8. PMID 28986966 DOI: 10.1117/1.Jbo.22.10.105001  0.019
2004 Hill B, Belville W, Bruskewitz R, Issa M, Perez-Marrero R, Roehrborn C, Terris M, Naslund M. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. The Journal of Urology. 171: 2336-40. PMID 15126816 DOI: 10.1097/01.ju.0000127761.87421.a0  0.019
1990 Price LA, Hill BT. Higher average received relative dose intensities of cyclophosphamide, methotrexate and 5-fluorouracil using a 24-hour method: Implications for improved cure rates in breast cancer Cancer Treatment Reviews. 17: 191-196. PMID 2272033 DOI: 10.1016/0305-7372(90)90046-I  0.019
2022 Scott E, Rowan S, Chandler K, Fisher A, Hill B, Hill J, Marx GE, Farrell E, Wendel K, Stella SA. Lessons Learned through Implementing SARS-CoV-2 Testing and Isolation for People Experiencing Homelessness in Congregate Shelters. Progress in Community Health Partnerships : Research, Education, and Action. 16: 13-22. PMID 35912653 DOI: 10.1353/cpr.2022.0034  0.019
2000 Perrin D, Gras S, van Hille B, Hill BT. Expression in yeast and purification of functional recombinant human poly(ADP-ribose)polymerase (PARP). Comparative pharmacological profile with that of the rat enzyme. Journal of Enzyme Inhibition. 15: 461-9. PMID 11030086  0.018
2007 Scully C, Boyle P, Day T, Hill B, Joshi V, Leupold NE, Shah JP, Lefebvre JL. International Consortium on Head and Neck Cancer Awareness (ICOHANCA). Oral Oncology. 43: 841-2. PMID 17720612 DOI: 10.1016/J.Oraloncology.2007.06.009  0.015
2019 Lam SW, Siebenaller C, Earl M, Hill BT, Kalaycio M, Rini B, Carraway HE, Leonard M, Sekeres MA. Descriptive comparison of hospital formulary decisions with published oncology valuation methods. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 1078155219877927. PMID 31594520 DOI: 10.1177/1078155219877927  0.015
1996 Perrin D, Halazy S, Hill BT. Inhibitors of the Ras signal transduction pathway as potential antitumour agents. Journal of Enzyme Inhibition. 11: 77-95. PMID 9204398  0.014
2022 Hill B, Khodaee M. Glenohumeral Joint Dislocation Classification: Literature Review and Suggestion for a New Subtype. Current Sports Medicine Reports. 21: 239-246. PMID 35801725 DOI: 10.1249/JSR.0000000000000973  0.013
2001 Hill BT, Fahy J. Preface Current Pharmaceutical Design. 7: xxx.  0.011
2019 Hill B, Gurley-Calvez T. Earned Income Tax Credits and Infant Health: A Local EITC Investigation National Tax Journal. 72: 617-646. DOI: 10.17310/NTJ.2019.3.06  0.01
2009 Heal CF, Weedon D, Raasch BA, Hill BT, Buettner PG. Agreement between histological diagnosis of skin lesions by histopathologists and a dermato-histopathologist. International Journal of Dermatology. 48: 1366-9. PMID 19930494 DOI: 10.1111/j.1365-4632.2009.04185.x  0.01
Hide low-probability matches.